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Background:  The National Institutes of Health (NIH) has implemented numerous policies to enhance 
stewardship of clinical trial grants.  These policies seek to improve identification, monitoring, oversight, 
completion, and results reporting of clinical trials.  Some of these policies have been met with concern 
from the researcher community regarding negative consequences on research.  To date, no systematic 
evaluations of the impact of these policies on research grant performance have been conducted.  This 
dissertation characterized the NIH clinical trial policies and evaluated how the key policies impacted a 
trial’s relative citation ratio and recruitment progress.  
Methods:  In Aim 1, I identified the new and revised NIH and National Institute of Mental Health (NIMH) 
clinical trial policies and summarized the potential benefits and potential burdens of those policies.  In 
Aim 2, I conducted an observational, single-group, pre/post evaluation of the association between the 
NIMH recruitment monitoring policy and the Relative Citation Ratio for NIMH-funded clinical trial grants.  
In Aim 3, I conducted a quasi-experimental study examining the effect of the new NIH clinical trial 
definition policy on recruitment progress.  Using a difference-in-differences design, this Aim compared 
recruitment progress before and after the policy took effect in a group of studies newly-identified as 
clinical trials under the policy relative to a comparison group of clinical trials unaffected by the new 
policy.   
Results:  In Aim 1, five new/revised NIH-wide and four NIMH-only clinical trial policies were identified.  
The potential benefits associated with these policies were the improved identification, review, conduct, 
and reporting of publicly-funded clinical trials.  Concerns over lost time, funding, and productivity due to 
administrative requirements were consistently identified as potential burdens. In Aim 2, a positive 
association was found between the implementation of a recruitment monitoring policy and the mean 
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relative citation ratio for clinical trial grants.  In Aim 3, the revised clinical trial definition policy had no 
effects on the recruitment progress in NIMH-funded grants at 20 months.   
Conclusions:  Further research is needed to affirm these results with larger and more representative 
samples.  Improved stakeholder engagement and planned policy outcome evaluation are recommended 




Beth McGinty, PhD, MS 
Readers: 
Gail Daumit, MD, MHS 
Brendan Saloner, PhD 
Roberta Scherer, PhD, MS 
Kevin Fain, DrPH, JD, MPH 
Alternates: 
Adam Spira, Ph.D. 





My time at the Johns Hopkins Bloomberg School of Public Health has been filled with wonderful 
interactions with phenomenal faculty and fellow students.  I am immensely grateful to my advisor, Beth 
McGinty, whose adept guidance and positivity made this dissertation an exciting adventure.  I 
appreciate the thoughtful critiques from my dissertation advisory committee which improved not only 
my research but also my professional skills.  I am thankful for the continual support of my family—
especially my wife Alejandra who was with me through every step of this journey.  Finally, I would like to 
thank my past and present colleagues in the Office of Clinical Research, primarily Pamela Shell and Nitin 




Table of Contents 
Abstract ......................................................................................................................................................... ii 
Acknowledgements ...................................................................................................................................... iv 
List of Tables ................................................................................................................................................ vi 
List of Figures .............................................................................................................................................. vii 
Introduction .................................................................................................................................................. 1 
Manuscript 1: Potential Benefits and Burdens of National Institutes of Health and National Institute of 
Mental Health Clinical Trial Policies .............................................................................................................. 3 
Abstract ..................................................................................................................................................... 3 
Introduction .............................................................................................................................................. 4 
Methods .................................................................................................................................................... 5 
Results ....................................................................................................................................................... 9 
Discussion................................................................................................................................................ 23 
Appendix: Search Terms ......................................................................................................................... 27 
References .............................................................................................................................................. 28 
Manuscript 2: Evaluating the Impact of the 2005 National Institute of Mental Health Policy for the 
Recruitment of Participants in Clinical Research on Relative Citation Ratios ............................................ 31 
Abstract ................................................................................................................................................... 31 
Introduction ............................................................................................................................................ 32 
Methods .................................................................................................................................................. 34 
Results ..................................................................................................................................................... 38 
Discussion................................................................................................................................................ 44 
References .............................................................................................................................................. 47 
Manuscript 3: Evaluating the Impact of the Revised National Institutes of Health Clinical Trial Definition 
on Recruitment Progress ............................................................................................................................ 48 
Abstract ................................................................................................................................................... 48 
Introduction ............................................................................................................................................ 49 
Methods .................................................................................................................................................. 51 
Results ..................................................................................................................................................... 56 
Discussion................................................................................................................................................ 62 
References .............................................................................................................................................. 65 
Integration and Policy Implications ............................................................................................................ 66 
Cross-cutting Themes and Implications .................................................................................................. 68 
Need for Future Research ....................................................................................................................... 69 





List of Tables 
 
Manuscript 1 
 Table 1. NIH Clinical Trial Policies in Effect in 2005 ……………………………………………………………….….10 
 Table 2. Comparison of Clinical Trial Definitions………………………………………………………….……………12 
 Table 3.  Summary of Potential Benefits and Burdens of NIH Clinical Trial Policies……………………18 
 Table 4. Current Policy Requirements for all NIH Clinical Trials………………………………………..……….20 




 Table 1. Sample Demographics by Fiscal Year……………………………………………………………………..…….41 
Table 2. Results of Multiple Linear Regression Analyses for Mean Grant and Maximum Grant 
Relative Citation Ratios…………………………………………………………………………….……………………………….44 
 
Manuscript 3 
 Table 1. Sample Demographics by Group (percents are column percents)………………………………..59 
 Table 2. Odds of On-Target Recruitment Progress at 20 Months in Control Group……………………60 
 Table 3. Odds of On-Target Recruitment Progress at 20 Months in Intervention Group ……..……61 
 Table 4.  Difference-in-Differences for Odds of On-Target Recruitment Progress at 20 Months..62  
vii 
 
List of Figures 
 
Manuscript 2 
 Figure 1: Sample Selection………………………………………………………………………………………………………..39 
Manuscript 3 





The National Institutes of Health (NIH) has developed and implemented numerous policies to 
enhance stewardship of clinical trial grants.  These policies seek to improve identification, monitoring, 
oversight, completion, and results reporting of clinical trials.  Some of these policies have been met with 
concern by the researcher community. To date, no systematic evaluations of the impact of these policies 
have taken place. This dissertation characterizes the NIH clinical trial policies and evaluates how key 
policies impact recruitment performance and relative citation ratios.   
To accomplish this goal, Aim 1 compiles and characterizes all NIH clinical trial policies 
implemented from 2005-2019 to establish the NIH-wide clinical trial policy landscape.  This 
characterization includes the policy goals, potential benefits, and potential burdens identified through 
public comments.  The NIH-wide policies establish a common standard, but individual Institutes/Centers 
within the NIH can implement additional policy structure to suit the needs of their mission (layering the 
Institute-specific policies on top of the NIH-wide policies).  With that in mind, this aim will also identify 
the scope of the Institute/Center-specific clinical trial policies of the National Institute of Mental Health 
(NIMH).  The NIMH was an early adopter of several clinical trial policies which were subsequently 
adopted as NIH-wide policies, including a recruitment milestone and reporting policy examined in Aim 2. 
 From the range of NIH policies characterized in Aim 1, the impact of two specific policies are the 
focus of Aims 2 and 3.  The first policy (Aim 2) is a recruitment milestone and reporting policy that 
requires clinical trials to establish timelines (milestones) for recruitment progress and update the NIH on 
that progress.  The NIH-wide implementation of this recruitment milestone and reporting policy is too 
recent (fiscal year 2019) for adequate outcome data collection, but the NIMH has had a similar policy in 
place since the start of fiscal year 2006.  The impact of the NIMH policy on the relative citation ratio, a 
grant performance outcome metric, can provide insight into the impact of the subsequent NIH policy. 
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The second policy (Aim 3) is a revision to the NIH definition of a “clinical trial.”  This policy was 
announced in 2014 and became effective for grant applications funded in fiscal year 2016.  NIH uses this 
definition in other policies to determine the applicability of numerous administrative requirements 
(identified in Aim 1).  Non-biomedical researchers have raised concerns that the revised definition, 
which expands the studies deemed clinical trials to include many studies testing social and basic 
behavioral interventions, imposes undue burden on research that is newly considered a clinical trial 
under the revised policy.  Therefore, the third aim of this dissertation examines the impact of the 
revised clinical trial definition on study progress for NIMH-funded clinical trials.  NIMH clinical trials were 
chosen because the NIMH began internally recording and tracking which NIMH-funded grants met the 
revised NIH definition of a clinical trial in FY2015 before the definition officially went into effect in 
FY2016 (and before formal NIH-wide tracking began in FY2019).  NIMH’s early tracking affords an 
opportunity to evaluate this policy before NIH-wide data are available.  The NIMH also funds many 





Manuscript 1: Potential Benefits and Burdens of National Institutes of 
Health and National Institute of Mental Health Clinical Trial Policies 
 
Abstract 
Background:  The National Institutes of Health (NIH) and the National Institute of Mental Health (NIMH) 
have implemented a suite of clinical trial policies in recent years.  These policies have well-intended 
goals but concerns of undue burden have been raised by basic behavioral science researcher 
organizations.  To date, no systematic characterization of these clinical trial policies has been performed.   
Methods: This study identified the new and revised NIH and NIMH clinical trial policies from 2005-2019 
and summarized the potential benefits and potential burdens of those policies.  The NIH and NIMH 
clinical trial policies were manually identified from the NIH Guide for Grants and Contracts.  Potential 
benefits and potential burdens were identified from a manual review of the policy notices, news articles, 
journal articles, press releases, websites, and official correspondence returned in searches of Google 
News, the Association for Psychological Science, the Federation of Associations in Behavioral & Brain 
Sciences, the American Psychiatric Association, and the American Psychological Association.   
Results: Five new/revised NIH-wide and four NIMH-only clinical trial policies were identified from fiscal 
years 2005-2019.  Potential benefits were the improved identification, review, conduct, and reporting of 
publicly-funded clinical trials.  Potential burdens were loss of researcher time, potential loss of future 
research funding opportunities for basic behavioral researchers, and widespread confusion (for both 
researchers and the general public) resulting from an overlap between clinical trials and basic science.   
Conclusions:  Future clinical trial policy development would benefit from early engagement of 
researchers as stakeholders.  The NIH and NIMH should publicly incorporate benefit/burden analyses 





The National Institutes of Health (NIH) is the largest biomedical research agency in the world 
(NIH, 2019d).  Over 80%, or over $31 billion USD, of the annual NIH budget is awarded through 
competitive grants and contracts to external researchers across the U.S. and internationally (NIH, 
2019c).  As a federal funding agency, the NIH must assure good stewardship of public funds and rigorous 
science (G.A.O., 2016).  This charge extends beyond the parent agency, the NIH, to the individual 
Institutes/Centers, such as the National Institute of Mental Health (NIMH), that issue awards in their 
relevant scientific mission.     
The framework for oversight of funded research can be described through an adaptation of 
Donabedian’s model for quality of care (Donabedian, 2005).  The Donabedian model describes the flow 
of influence from an organization’s structure to its processes and from the processes to the outcomes.  
Changing one element can have an impact on the downstream elements; therefore, outcomes can be 
influenced positively or negatively by processes and by structure.  The NIH establishes a structure for 
research by requiring grantees to follow policies outlined in the terms and conditions of the grant 
award.  The NIH-wide policies lay a structural foundation for all grants, while Institute/Center-specific 
policies, such as those of the NIMH, continue to build upon that foundation.  Because grant funding is 
dependent upon compliance with this policy structure, the NIH and NIMH can use the policies to 
influence the downstream research process at grantee research institutions.  Further downstream, the 
NIH can evaluate the effect on outcomes through research publications, results reporting in 
ClinicalTrials.gov, and potentially other metrics such as changes to clinical guidelines. 
Despite this structure, the NIH has historically struggled to provide data to demonstrate full 
stewardship of clinical trials across the agency (G.A.O., 2016).  In 2016, an evaluation by the Government 
Accountability Office (GAO) recommended that the NIH “(1) finalize data on clinical trial activity that the 
[Office of the NIH Director] needs to collect from Institute/Centers, and (2) establish and implement a 
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process for using those data (G.A.O., 2016).”  In response, the NIH launched a comprehensive set of 
policy initiatives to “ensure rigor, transparency, and effectiveness of the US federally-funded clinical trial 
enterprise” beginning that same year and continuing through 2019 (Lauer & Wolinetz, 2016; NIH/OER, 
2017b).  Grantees have repeatedly expressed concern that the burden of compliance with these clinical 
trial policies will slow scientific progress (NIH, 2016a).   
The goals of this study are to identify and summarize the scope, potential benefits, and potential 
burdens of both the NIH-wide and NIMH-specific clinical trial policies.  The range of policies 




 This study systematically identified and summarized the potential benefits and burdens of NIH-
wide and NIMH-specific clinical trial policies from Fiscal Year 2005-2019.  Clinical trial policies were 
defined as any policy which set different or additional expectations or requirements for NIH-funded 
grants with clinical trials in human subjects as compared to grants with non-trials in human subjects.  
General human subjects research policies that apply to all research with humans are not clinical trial-
specific policies and do not fall within the scope of this project.  Potential benefits were defined as 
potential positive outcomes described as likely to result from a specific clinical trial policy.  Potential 
benefits could be prospectively identified by the NIH/NIMH (“intended benefits”) or subsequently by 
external stakeholders (“perceived benefits”).  Potential burdens were defined as potential negative 
outcomes described as likely to result from a specific clinical trial policy.  Potential burdens could be 
forecasted by the NIH/NIMH (“anticipated burdens”) or by external stakeholders (“perceived burdens”).  
The fiscal year (FY) corresponds to the Federal Fiscal Year, which begins on October 1st of the previous 
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calendar year and ends on September 30th of the same year (e.g., FY2005 was October 1, 2004 through 
September 30, 2005). 
 
Identification of Documents Describing Clinical Trial Policies, Potential Benefits, and Potential Burdens 
Identifying Clinical Trial Policies 
The NIH Grants Policy statement contains the full requirements of policies, terms, and 
conditions for accepting NIH funding to conduct research (NIH, 2018b).  When new NIH or NIMH policies 
are announced, or existing policies are revised, this information is published in the NIH Guide for Grants 
and Contracts as a notice.   Notices announced in the NIH Guide for Grants and Contracts supersede the 
Grants Policy Statement until the policy is incorporated into the next revised version of the Grants Policy 
Statement (NIH, 2018b).   
The version of the NIH Grants Policy Statement in effect for FY2005 was reviewed to identify the 
existing clinical trial requirements at that time.  Following the identification of clinical trial policies in 
effect in FY2005, the NIH Guide for Grants and Contracts was examined for NIH-wide and NIMH-specific 
clinical trial policy notices from FY2005-2019.  Using the Guide’s search function, the results were 
filtered for notices containing the word “trial.”  The returned results were reviewed by hand to 
determine whether the notice included a clinical trial policy, defined as text explicitly establishing an 
NIH/NIMH requirement that applies to a clinical trial grant application or award but does not apply to a 
non-trial application/award. 
Identifying Potential Benefits and Potential Burdens 
Potential benefits and potential burdens were identified from: the policy notice; NIH/NIMH 
public announcements; and searches of Google News, the Association for Psychological Science (APS), 
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the Federation of Associations in Behavioral & Brain Sciences (FABBS), the American Psychiatric 
Association, and the American Psychological Association.  The search terms were the exact policy title 
and/or the policy announcement control number (see appendix).  Google News was chosen to capture 
potential press releases and news coverage of policies and implications.  The APS and FABBS were 
identified in formative research as the primary professional societies coordinating commentary on 
behalf of their members and other concerned professional organizations.  The websites of the American 
Psychiatric Association and the American Psychological Association were also searched using the same 
methodology; however, these associations did not release independent press statements.  Instead, they 
submitted their statements through FABBS (as co-signatories).  Search results returned news articles, 
journal articles, press releases, webpages with relevant content, and official correspondence (i.e., 
publicly disclosed letters between NIH and aforementioned parties).   
 
Data Abstraction  
Abstraction Process 
Potential benefits and potential burdens were identified from a manual review of the policy 
notices, news articles, journal articles, press releases, websites, and official correspondence returned in 
the search results.  Formal NIH responses (i.e., direct correspondence in reply to letters sent by 
stakeholders to NIH) to concerns of burden were identified during data abstraction.  In some cases, the 
NIH response was an alteration of the policy interpretation or implementation.  Therefore, each NIH 
response was hand-reviewed to identify if the response changed the clinical trial policy (including a 





The data were collected in a Microsoft Excel spreadsheet for consolidation and analysis.  
Measures used to characterize the data were: type of notice, policy number (NIH Guide notice number), 
policy title, announcement date, effective date, effective fiscal year, policy summary, intended benefits 
(identified by NIH/NIMH), anticipated burdens (identified by NIH/NIMH), perceived benefits (identified 




  Through this analysis, the policy intent and rationale were summarized from the policy notice 
for each NIH-wide clinical trial policy.  The intended and perceived benefits, anticipated and perceived 
burdens, and subsequent NIH alterations were then identified and summarized for each policy.  The 
NIMH-specific clinical trial policies were identified and summarized using the same methodology.  The 
initial NIH-wide clinical trial requirements and the subsequent 2005-2019 NIH and NIMH clinical trial 
policies were collated chronologically by effective fiscal year to establish a timeline of changes and 
current policy requirements. 
 
Limitations 
The frequency of result “hits” could not be identified because many of the same burdens were 
either repeated or "co-issued" as joint statements between various groups.  In some cases, 2 
organizations would identify the same burden separately, or a single organization would publish the 
same burden concern numerous times in different formats.  Because formal evaluations of the 
9 
 
magnitude of benefit/burden are not available, this summary was limited to focusing on published 
potential benefits and potential burdens rather than actual measured benefit/burden.  Additionally, a 
summary of perceived burdens for the NIMH-specific policies was not possible because all returned 
results were NIMH-authored (i.e., no results from non-NIMH sources).   
 
Results 
The search of clinical trial policies returned 1620 NIH-wide and 761 NIMH-only notices published 
in the NIH Guide to Grants and Contracts from FY2005-2019.  Of these, 90 NIH-wide notices and 168 
NIMH-only notices contained the word “trial.”  After hand review of the notice summaries, 42 NIH-wide 
notices and 19 NIMH-only notices were determined to be directly related to clinical trials.  This subset of 
notices was then reviewed further to determine whether each notice met inclusion criteria.  In total, five 
new NIH-wide and another five new NIMH-specific clinical trial policies were identified.  For the five NIH-
wide clinical trial policies, the potential benefits identification process returned nine news articles and 
seven NIH postings while the potential burden identification returned nineteen news articles, three APS 
results, twelve FABBS results, and one NIH posting.  The results also returned three NIH letters, six NIH-
authored blog posts/articles, and one news article responding to perceived burdens.   
 
Existing 2005 NIH Clinical Trial Policies 
There were four clinical trial-specific policies that were in effect in 2005, the start of the study 
period (NIH, 2003).  These existing policies are summarized in Table 1.  The first policy defined the 
“clinical trial” term (see Table 2).  The second policy defined Phase III clinical trials.  The third policy 
mandated a formal data and safety monitoring plan (DSMP) for all clinical trials commensurate with the 
size and complexity of the trial.  The DSMP is evaluated as part of the peer-review process.  This policy 
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also identifies key factors for determining the frequency of monitoring, determining the person/persons 
responsible for conducting the monitoring, and the frequency and method of reporting safety events to 
other oversight entities.  The fourth policy is the requirement for Data and Safety Monitoring Boards 
(DSMB) for multi-site clinical trials involving risks to participants and generally for phase III trials.   
 
Table 1. NIH Clinical Trial Policies in Effect in 2005  
Policy Policy Summary 
Clinical Trial Definition Defined term “clinical trial” for NIH-funded research.  See Table 2. 
Phase III Clinical Trial 
Definition  
Definition: “Clinical investigation (usually involving several hundred or 
more human subjects) to evaluate an experimental intervention in 
comparison with a standard or control intervention or to compare two or 
more existing treatments.” 
Data and Safety 
Monitoring Plans 
NIH requires a formal data and safety monitoring plan to ensure the safety 
of participants and the validity and integrity of the data as part of the 
peer-reviewed funding application.  The planned level of monitoring 
should be commensurate with the risks and the size and complexity of the 
clinical trial. 
Data and Safety 
Monitoring Boards 
NIH requires the establishment of DSMBs for multi-site clinical trials 
involving interventions that entail potential risk to the participants and 
generally for phase III clinical trials. 
 
FY2005-2019 Clinical Trial Policies 
Five new/revised NIH clinical trial policies put in place between fiscal year 2005 and fiscal year 
2019 were identified.  The first policy, entitled “Provision of Antiretroviral Treatment for Trial 
Participants Following their Completion of NIH-Funded HIV Antiretroviral Treatment Trials in Developing 
Countries,” required investigators/contractors to address the provision of antiretroviral treatment to 
trial participants after their completion of the trial for antiretroviral treatment trials conducted in 
developing countries (NIH, 2005).  While the notice itself was a guidance document, it did state that the 
NIH expected a plan to be included when considering funding decisions (making the plan a de facto 
requirement).   
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The second policy, entitled “Notice of Revised NIH Definition of ‘Clinical Trial,’” redefined which 
studies NIH considers a clinical trial (NIH, 2014b).  Table 2 compares the old NIH definition, the revised 
NIH definition, the definition shared by both the World Health Organization (WHO) and the International 
Committee of Medical Journal Editors (ICMJE), and the definition used by other US Government 
agencies in the federal Common Rule.  As illustrated in table 2, the revised NIH definition is more 




Table 2. Comparison of Clinical Trial Definitions 
Organization Clinical Trial Definition Comparison to current NIH 
definition 
NIH (pre-2014)  
(NIH, 2003) 
A biomedical or behavioral research 
study of human subjects that is 
designed to answer specific questions 
about biomedical or behavioral 
interventions (drugs, treatments, 
devices, or new ways of using known 
drugs, treatments, or devices). 
Pre-2014 definition is broad and 
does not link the effect of 
interventions to health-related 
outcomes.  Examples provided in 
the policy are primarily 
biomedical. 
 
NIH Current (post-2014) 
(NIH, 2014b) 
A research study in which one or 
more human subjects are 
prospectively assigned to one or 
more interventions (which may 
include placebo or other control) to 
evaluate the effects of those 
interventions on health-related 
biomedical or behavioral outcomes. 
Current NIH definition 
WHO/ICMJE 
(ICMJE, n.d.-b; WHO, 
n.d.) 
Any research project that 
prospectively assigns people or a 
group of people to an intervention, 
with or without concurrent 
comparison or control groups, to 
study the cause-and effect 
relationship between a health-
related intervention and a health 
outcome. 
WHO/ICMJE definition includes 
requirement that the intervention 
is health-related.  WHO/ICMJE 
define health-related 
interventions as those used to 
modify a biomedical or health-
related outcome.  Consistent with 
NIH definition which uses the 
same criteria to define 
intervention (NIH/OER, 2017a). 
Federal “Common Rule” 
(DHHS, 2017) 
A research study in which one or 
more human subjects are 
prospectively assigned to one or 
more interventions (which may 
include placebo or other control) to 
evaluate the effects of the 
interventions on biomedical or 
behavioral health-related outcomes.  
Equivalent to NIH definition 
(NIH/OER, 2017a). 
 
The third new clinical trial policy, entitled “Policy of Funding Opportunity Announcements (FOA) 
for Clinical Trials,” required that all applications involving one or more clinical trials be submitted 
through a Funding Opportunity Announcement (FOA) specifically designed for clinical trials (NIH, 2016b).  
This policy was announced in September 2016 and became effective for grants funded in fiscal year 
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2019 and later.  With this new policy, the NIH would no longer accept NIH-defined clinical trial funding 
applications under announcements that are not specifically designed to accept clinical trials.  In concert 
with these revised announcements, the grant application form was revised to more clearly identify 
clinical trial applications and describe key elements of the clinical trial design as well as identify 
recruitment and inclusion targets and milestones (NIH, 2017a).  Further, applications submitted under 
these new clinical trial funding opportunity announcements would be evaluated using clinical trial-
specific review criteria (NIH, 2017b). 
The fourth new clinical trial policy, entitled “Policy on Good Clinical Practice Training for NIH 
Awardees Involved in NIH-funded Clinical Trials” was announced in September 2016 with an effective 
date of January 1, 2017 for any active and future NIH-funded clinical trials (NIH, 2016c).  This policy 
established NIH’s expectation for clinical trial awardees that clinical trial staff would be trained in Good 
Clinical Practice (GCP) consistent with the International Conference on Harmonisation. 
The fifth new clinical trial policy, entitled “NIH Policy on the Dissemination of NIH-Funded 
Clinical Trial Information” was announced in September 2016 with an original effective date of January 
2017 (NIH, 2016a).  This policy required that any NIH-funded clinical trial must register with and report 
results to ClinicalTrials.gov.  This policy notice followed a request for public comment on the proposal 
(NIH, 2014a).  The clinical trial policies, potential benefits, and potential burdens are summarized in 
Table 3.   
 
Intended/Perceived Benefits 
 Numerous proposed benefits were attributed to these new clinical trial policies.  The policy 
requirement to address post-trial antiretroviral therapy access was perceived by NIH and other 
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stakeholders to reduce the risk of subsequent treatment failure due to lapsed/interrupted treatment 
upon study completion (NIH, 2005; Shah, Elmer, & Grady, 2009).   
NIH identified five intended benefits of the revised definition of “clinical trial.”  This policy was 
intended to (1) clarify the definition, (2) improve the identification and tracking of clinical trials, (3) 
enhance the NIH’s review of clinical trial applications, and (4) ensure investigators are meeting their 
obligations related to conducting clinical trials and improve the oversight and transparency (i.e. results 
sharing) of clinical trials, (NIH, 2014b; NIH/OER, 2017b).  The NIH also stated that the revised definition 
was intended to (5) help the NIH to fund mission-relevant, high-priority trials without needlessly 
duplicating previously conducted trials (Hudson, Lauer, & Collins, 2016).  These NIH leaders noted that 
clinical trials frequently suffer from poor design and structure and many trials fail to publish results or 
submit data to a public database.   
NIH identified three intended benefits of the clinical trial-specific funding opportunity 
announcement policy.  In the policy announcement and companion article, NIH stated that this policy 
was intended to (1) improve NIH's ability to identify proposed clinical trials, (2) ensure that key pieces of 
trial-specific information are submitted with each application, and (3) uniformly apply trial-specific 
review criteria that focus on trial rationale, design, and analysis plans (Hudson et al., 2016; NIH, 2016b). 
Three intended benefits of the GCP training policy were identified.  The policy announcement 
proposed that the policy would (1) improve the safety of human research participants, (2) increase the 
scientific rigor, and (3) increase the reliability of study data (NIH, 2016c).  NIH noted that GCP training 
provides a consistent and high-quality standard for conducting clinical trials (Hudson et al., 2016).   
The ClinicalTrials.gov registration and results reporting policy received significant public support 
for both the proposal and its application to all NIH-funded clinical trials particularly since these trials are 
funded with public money (NIH, 2016a).   Four potential benefits of the policy were identified.  (1) NIH 
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proposed that the availability of results information will benefit investigators who will have access to 
more data, IRBs when evaluating risks and benefits, and the general public (NIH, 2016a).  (2) NIH also 
proposed that the policy would reduce unintended duplication by providing more complete information 
for potential funders (Hudson et al., 2016).  The ICMJE and various NIH authors proposed that the policy 
(3) fulfilled an ethical obligation to publicly share clinical trial data since participants placed themselves 
at potential risk to contribute to generalizable knowledge and (4) improved science by reducing 
publication bias and advancing the knowledge base of a field (ICMJE, n.d.-a; Taichman et al., 2016; Zarin, 
Tse, Williams, & Carr, 2016). 
 
Anticipated/Perceived Burdens 
As shown in Table 3, most potential burdens were perceived burdens identified by external 
stakeholders.  Many of the perceived burdens were not identified as anticipated burdens by NIH in the 
policy notices or accompanying articles. 
Two potential burdens of the antiretroviral treatment access planning policy were identified.  
First, the NIH acknowledged that its own authority to “encourage and support research” does not 
extend to supporting treatment provision following the completion of that research (NIH, 2005).  
Second, the policy may establish differential expectations for the provision of care to trial participants 
versus non-participants in those regions (Millum, 2011). 
While the policy revising NIH’s definition of clinical trial was announced in 2014, basic behavioral 
researchers (ranging from brain researchers to basic psychosocial researchers) were unaware that the 
changes would significantly impact their research until the three subsequent policies (GCP training, 
ClinicalTrials.gov registration, and clinical trial-specific FOAs/review criteria) were released in 2016 
(Kaiser, 2017).  Consequently, many of the perceived burdens for these policies were identified and 
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expressed in joint-society letters to the NIH.  These joint-society letters were identified through the APS 
and the FABBS.   
With respect to the revised clinical trial definition, the APS commented that the policy forces 
basic research with human subjects into the clinical trial definition (APS, 2018b).  As a result, the APS 
expressed significant concern that the policy could place “undue burden” on researchers in terms of the 
application process, conduct of research, and monitoring of research (APS, 2017, 2018a).  Similarly, the 
FABBS expressed concern that classifying such research a clinical trial would “impose a raft of new 
requirements” and “cripple exploratory research” (Kaiser, 2017).  The FABBS outlined seven specific 
concerns (encompassing all new clinical trial policies) to the NIH.  The perceived burdens identified by 
FABBS were: (1) definition of clinical trials includes basic science research; (2) basic scientists not 
consulted, yet impacted; (3) creating public confusion about the nature of studies in ClinicalTrials.gov; 
(4) NIH policy may decrease funding opportunities for basic scientists; (5) increases burden on 
investigators without a clear rationale; (6) penalties for noncompliance are significant; and (7) 
mandatory training is focused on clinical trials, not the type of research actually being funded and 
conducted (FABBS, 2017a).   
Two perceived burdens were attributed to the clinical trial-specific FOAs and review criteria 
policy.  First, an open letter to the NIH Director expressed concern that basic research applications now 
classified as clinical trials would be reviewed and scored by review panels who might not understand the 
nuances of basic discovery research which could potentially lead to lost research funding (FABBS, 2017a; 
Wolfe, 2017).  Second, concerns were also expressed that difficulty identifying the appropriate funding 
opportunity announcement for clinical trials in basic science could delay funding and harm researchers 
(APS, 2016; FABBS, 2017a). 
17 
 
Two perceived burdens of the GCP training policy mandate were (1) the time commitment and 
(2) the training may have an inappropriate biomedical focus for basic behavioral science researchers 
(FABBS, 2017a). 
Four potential burdens were identified resulting from the ClinicalTrials.gov registration and 
reporting policy.  In the summary of public comments, NIH noted that some respondents were 
concerned that (1) the risks of burden and cost outweighed the benefit of transparency and (2) the 
timeline for reporting information was too short for academics with competing responsibilities at 
universities (NIH, 2016a).  While multiple professional societies expressed support for the overarching 
goals of registration and results reporting for all human subjects research (clinical trials and non-trials 
alike), they noted additional perceived burdens: (3) monetary penalties for non-compliance and (4) 
researcher and public confusion resulting from using ClinicalTrials.gov rather than a platform designed 
for basic science research studies (FABBS, 2017b, 2018).  The United States Congress noted these 
concerns and instructed NIH to delay inclusion of basic research studies under the policy until after the 





Table 3.  Summary of Potential Benefits and Burdens of NIH Clinical Trial Policies 
Policy Effective FY Potential Benefits Potential Burdens 
Planning Post-Trial 
Access to Antiretroviral 
Treatments 
2005 1. Reduces risk of 
treatment failure1,2 
1. NIH does not pay for post-
trial access1 
2. Sets unequal expectations 
within patient community5 
Revised Clinical Trial 
Definition 
2016 1. Clarified definition1 
2. Improved identification 
and tracking of clinical 
trials1 





5. Reduce unnecessary 
duplication of effort1 
1. New definition overlaps 
with basic research 
definition6,7 
2. Confuses researchers and 
general public6,7 
3. Subjects some basic science 





2019 1. Improved identification 
of clinical trials1 
2. Improve information 
available to peer 
reviewers1 
3. Uniformly apply trial-
specific review criteria1 
1. Loss/reduction in funding 
for basic science researchers6,7 
2. Rejection of applications 
when submitted to incorrect 
FOA6,7 
Good Clinical Practice 
Training Mandate 
2017 1. Increase trial safety for 
participants1 
2. Increase scientific rigor 
of trials1 
3. Increase reliability of 
study data1 
1. Time commitment6,7 








1. More access to data for 
investigators and IRBs1 
2. Better historical 
information for funding 
sponsors1 
3. Ethical obligation for 
publicly-funded research 
data1,3,4 





2. Time commitment6,7 
3. Monetary penalties for non-
compliance7 
4. Inappropriate 
repository/structure for basic 
science data7 
1 = NIH; 2 = (Shah et al., 2009); 3 = ICMJE; 4 = (Zarin et al., 2016); 5 = (Millum, 2011); 6 = Association for 
Psychological Science; 7 = Federation of Associations in Behavioral & Brain Sciences  




NIH Responses to Concerns 
 Attempts by NIH to address some of the perceived burdens were identified.  To address the 
concern that existing GCP training options were not geared toward basic behavioral research studies, 
the NIH partnered with the Society of Behavioral Medicine to develop a free GCP training module for the 
research community (OBSSR, 2017).  To help researchers understand the revised clinical trial definition, 
NIH developed a series of decision aids and case studies to aid potential grant applicants with 
determining whether a research study is a clinical trial (NIH/OER, 2016).  However, NIH acknowledged 
that some research studies simultaneously meet the federal definitions of basic research and clinical 
trial but noted that the NIH definition is consistent with similar definitions in the field (table 2).  Those 
studies were named Basic Experimental Studies involving Humans (BESH) to allow for specific 
identification and assistance.  BESH studies are those that “prospectively assign human participants to 
conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or 
behavioral outcomes in humans for the purpose of understanding the fundamental aspects of 
phenomena without specific application towards processes or products in mind” (NIH, 2019b). 
In July 2018, the NIH issued a policy notice entitled “Delayed Enforcement and Short-Term 
Flexibilities for Some Requirements Affecting Prospective Basic Science Studies Involving Human 
Participants” (NIH, 2018a).  This notice delayed the requirement to register and report BESH studies in 
ClinicalTrials.gov until September 2019.  During this delay, BESH clinical trials must still register and 
submit results, but can do so on a public platform designed for basic research.  The policy enforcement 
delay also included an announcement that BESH-specific funding opportunity announcements would be 
published to reduce confusion.  The policy delay was viewed as a positive step by the concerned 
societies (Kaiser, 2018b).  The NIH issued a request for information in August 2018 to seek input 
regarding how best to implement the NIH Policy on the Dissemination of NIH-Funded Clinical Trial 
Information for prospective basic science studies involving human participants (BESH studies) (NIH, 
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2018c).  While considering the comments received, the NIH continues to examine potential changes to 
ClinicalTrials.gov and has subsequently delayed the BESH study registration and reporting requirements 
to that platform until 2021 (NIH, 2019a; Wolinetz, Lauer, & Riley, 2019).  Current (September 2019) 
clinical trial policy NIH requirements for standard (non-BESH) and BESH clinical trials are summarized in 
Table 4.  
Table 4. Current Policy Requirements for all NIH Clinical Trials 
Non-BESH Clinical Trial BESH Clinical Trial 
1. Funding application submitted to clinical trial-
specific Funding Opportunity Announcement 
1. Funding application submitted to BESH clinical 
trial-specific Funding Opportunity Announcement 
2. Provision of key clinical trial information in 
funding application including data and safety 
monitoring plan 
2. Provision of key clinical trial information in 
funding application including data and safety 
monitoring plan 
3. DSMB oversight of multi-site clinical trials that 
entail potential risk to participants 
3. DSMB oversight of multi-site clinical trials that 
entail potential risk to participants 
4. Good Clinical Practice training for study staff 4. Good Clinical Practice training for study staff 
5. Registration and results reporting to 
ClinicalTrials.gov 
5. Registration and results reporting to 
ClinicalTrials.gov or existing basic science portals 





NIMH-specific Clinical Trial Policies 
In addition to the NIH-wide clinical trial policies, the NIMH has also published five NIMH-specific 
clinical trial policies.  These policies apply only to research that is funded by the NIMH and are 
summarized in Table 5.   The first policy, entitled “NIMH Policy for Submission of Applications Containing 
Clinical Trials” required that clinical trial applications must be submitted to an NIMH clinical trial-specific 
funding opportunity announcement (NIMH, 2014b).  This policy was effective for grants funded in 
FY2015.  The policy is consistent with the NIH-wide clinical trial-specific FOA policy, but the requirement 
preceded the NIH-wide policy by four years.  NIMH identified the intended benefit of this policy as 
improvement in efficiency, transparency, and human subject protection in clinical trials (Insel & Gogtay, 
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2014, 2015).  One anticipated burden identified in the policy announcement was that clinical trial 
applications submitted to non-clinical trial FOAs would not be accepted for review or funding. 
A second NIMH-specific clinical trial policy, entitled “Data Sharing Expectations for NIMH-funded 
Clinical Trials” went into effect in FY2015 (NIMH, 2014a).  This funding policy established that NIMH-
funded clinical trials would share data via a new common informatics platform developed by the NIMH.  
Given the concerns that NIMH-funded clinical trials were not publishing results in a timely manner, the 
NIMH proposed that this platform (and sharing mandate) would have significant value to the research 
community and accelerate scientific discovery (Brauser, 2014; NIMH, 2014a).  Further, the financial cost 
of data sharing could be charged directly to the grant, thereby alleviating financial burden (NIMH, 
2014a).  While this data sharing policy briefly began as a clinical trial-specific policy, it was quickly 
expanded to all NIMH-funded research involving human subjects in subsequent policies which 
harmonized the clinical trial and non-trial expectations in FY2016 (NIMH, 2015a, 2019).  Therefore, this 
policy is no longer a clinical trial-specific policy because the requirement now applies to all clinical 
research.  
The third NIMH-specific clinical trial policy, entitled “NIMH Policy Governing the Monitoring of 
Clinical Trials” went into effect in FY2016 (NIMH, 2015b, 2015c).  This policy built upon the NIH-wide 
requirement for data and safety monitoring in all clinical trials by stating the need for a clear and well-
developed data and safety monitoring plan (DSMP), identifying the critical elements of a DSMP, 
outlining the appropriate levels of monitoring for a clinical trial, and assuring the NIMH is notified by 
NIMH-funded researcher of the outcomes of those monitoring activities (NIMH, 2015b).   
In the same announcement, the NIMH issued the fourth NIMH-specific clinical trial policy, 
entitled “Policy Governing Independent Safety Monitors and Independent Data and Safety Monitoring 
Boards” which also went into effect in FY2016 (NIMH, 2015b).  This policy clarified when and how 
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independent safety monitors (ISM) and data and safety monitoring boards (DSMB) should be used for 
NIMH-funded clinical trials (NIMH, 2015d).  The goal of these two companion policies was to ensure the 
safety of research participants in NIMH-funded clinical trials. 
The fifth NIMH-specific clinical trial policy, entitled “Change to NIMH Policy for Recruitment of 
Participants in Clinical Research” required all new clinical trial awards to establish recruitment 
milestones and report progress triannually effective FY2017 (NIMH, 2016).  NIMH proposed that this 
policy improves oversight leading to successful recruitment and study completion.  Previously, the policy 
only applied to human research studies with a sample size greater than 150 participants.  This policy 
change expanded the scope to include all clinical trials regardless of size.  NIH requires the 
establishment of recruitment milestones and progress reporting on an annual basis.  The NIMH’s 
triannual recruitment reporting policy is more frequent and preceded the NIH-wide tracking of clinical 
trial recruitment data in the annual progress report by two years. 
 
Table 5.  Summary of Intended Benefits and Anticipated Burdens of NIMH-Specific Clinical Trial 
Policies 






2015 1. Improved efficiency, 
transparency, and human 
subject protection. 




NIMH Data and Safety 
Monitoring Policy 











2005: Sample size ≥150 
2017: All clinical trials 
1. Improve likelihood of 
successful study recruitment 
and completion. 
None identified. 
Note:  Searches for potential benefits or burdens from non-NIMH sources returned no results.  All 





 The NIH implemented five clinical trial policies between fiscal years 2005 and 2019.  The NIMH 
implemented four clinical trial policies during the same time period.  The results are consistent with the 
previously discussed adaptation of Donabedian’s model.  The NIH/NIMH policies were designed and 
implemented to build structure with the intent of improving processes and subsequently grant 
performance outcomes.  Because the clinical trial policies are intertwined, common themes were 
identified for both potential benefits and potential burdens.  The clinical trial definition policy, as the 
foundation for the subsequent policies in this analysis, was often discussed alongside the other 
individual policies.  The NIH engaged stakeholders during implementation of some policies, but both NIH 
and NIMH should consider involving stakeholders earlier during development for future policies.  In 
numerous articles, researchers and professional organizations noted that they were unaware of the 
forthcoming policy changes until after the policies were announced and were therefore unable to 
engage in the policymaking process.  Both agencies should also consider building outcome evaluation 
into the policy development process. 
 The ubiquitous rationale for the recent clinical trial policies was the need for quality 
improvement of the identification, review, conduct, and output from NIH-funded research.  
Consequently, the NIH/NIMH saw these elements, along with increased human subject protection, as 
the intended benefits across all of the policies characterized in this study.  Similarly, the basic behavioral 
science research community identified cross-cutting perceived burdens resulting from these policies.  
These repeating themes were loss of research time (through time spent troubleshooting unclear 
applications/forms, taking irrelevant mandated trainings, or navigating incompatible data repositories); 
potential loss of future research funding; and widespread confusion about a definition that seemed to 
suddenly envelope a previously distinct field.  The intended benefits and perceived burdens repeat 
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across each clinical trial policy because the core disagreement begins (and to some degree ends) with 
the definition of a clinical trial.  
The clinical trial definition was the most contentiously debated policy.  The revised definition 
appears to capture a wider subset of studies than the previous definition.  The policy definition is 
consistent with the other definitions currently used by other federal agencies and the ICMJE; however, 
unlike those definitions, the NIH’s definition is operationalized to determine the applicability of 
administrative requirements and other NIH policies including DSMP/DSMB requirements, funding 
opportunity announcements, review criteria, GCP training, and ClinicalTrials.gov registration and results 
reporting requirements.  Each of these policies is intended to push better identification, review, 
tracking, accountability, oversight, and transparency; increased rigor and participant safety; and better 
scientific progress through better science and data sharing.  Despite these intended benefits, the lack of 
engagement with the research community, specifically basic behavioral researchers, has proven 
problematic.  The revised clinical trial definition was not well discussed with stakeholders leading to 
confusion and general disagreement.  Researchers have repeatedly expressed concerns that the new 
definition (and downstream applicability of other clinical trial policies) will result in confusion (for 
researchers and public); increased time burden for researchers; financial burden for grantees; and 
potential for miscommunication with the public over the very nature of clinical trials. 
In response to the concerns of basic behavioral science researchers, the NIH implemented basic 
behavioral science focused GCP training, BESH-only FOAs, and flexibility for BESH clinical trial 
registration and results reporting.  The NIH attempted to reduce the perceived burdens and address the 
concerns of the research community, but some concerns, such as administrative burden, continued to 
be expressed after these efforts.  While it is unlikely that any policy change will please all stakeholders, 
the NIH could have worked with these groups during the policy development phase to build consensus 
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and agreement upon the rationale for the changes and necessary adjustments to accommodate a wider 
range of studies now considered clinical trials.    
NIH did not plan for or evaluate objective measures of benefit or burden that could be used for 
future policy development or revision.  Interestingly, the NIMH implemented clinical trial-specific FOAs 
in FY2015 – four years before NIH (2019).  The NIMH also began participant recruitment tracking for 
many studies in 2005 and expanded this to all clinical trials in FY2017 (also preceding the NIH-wide 
policy).  Much like NIH, the NIMH stated the intended benefit and rational for each of these policies, but 
unfortunately did not formally evaluate anticipated burdens of the NIMH-specific clinical trial policies 
(no public comments were identified either).  Still, the early NIMH implementation of policies similar to 
the NIH policies represents an opportunity to evaluate the changes in outcomes due to the NIMH-
specific policies as a prediction model for the later NIH-wide policies.  For example, concerns that 
administrative burdens delay research can be examined by evaluating research participant recruitment 
progress for ongoing studies and time to result reporting (in ClinicalTrials.gov) in completed studies.  
Over time, the impact of the policies on research outcomes could also be evaluated through examining 
changes in clinical practice or impact on scientific influence through the Relative Citation Ratio 
(Hutchins, Yuan, Anderson, & Santangelo, 2016).  Both NIH and NIMH should incorporate outcome 
evaluation into the policy development process.   
 There are a several limitations to this study.  First, the identification of potential benefits and 
potential burdens is limited to existing published statements rather than direct surveying of key 
stakeholders.  Consequently, first-hand experiences with burden of implementation and compliance 
were not within the scope of this study.  Further, the intertwining nature of how these concerns were 
voiced (co-issued and/or repeat issued) limited the ability to discuss magnitudes or frequencies.  
Second, the lack of formal public comment on the NIMH-only policies limited the summary of potential 
burdens to only those that were anticipated by NIMH.  Third, this study examines only NIH and NIMH 
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policies and does not include additional requirements from other federal agencies such as the Food and 
Drug Administration or the HHS Office for Human Research Protections.  Finally, this descriptive study 
does not validate the identified statements of potential benefits or potential burdens.  
Both the NIH and the NIMH have implemented clinical trial policies to build structure with the 
intent of influencing process and outcomes; however, neither NIH nor NIMH appear to have examined 
the potential burdens during early policy development.  The NIH and NIMH should consider engaging 
stakeholders, through advisory groups or solicitation of public comment, during major policy 
development.  NIH/NIMH should formally evaluate and discuss potential benefits/burdens in the policy 
rationale for future science policies.  Further, both agencies should consider incorporating outcome 
evaluation into future policy development.  Finally, both NIH and NIMH should consider post-
implementation evaluation of the policy impact on researchers which may include direct surveys to 
measure the magnitude of actual benefits or burdens. 
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Appendix: Search Terms  
The following search terms were used to identify benefits and burdens as described in the methods 
section.  Data sources were searched individually for each term.  The results were aggregated by hand. 
Search terms: 
“NOT-OD-05-038” 
“Guidance for Addressing the Provision of Antiretroviral Treatment for Trial Participants Following their 
Completion of NIH-Funded HIV Antiretroviral Treatment Trials in Developing Countries“ 
“NOT-OD-15-015“ 
“Notice of Revised NIH Definition of “Clinical Trial” 
“NOT-OD-16-147“  
“Policy on Funding Opportunity Announcements (FOA) for Clinical Trials“ 
“NOT-OD-16-148“  
“Policy on Good Clinical Practice Training for NIH Awardees Involved in NIH-funded Clinical Trials“ 
“NOT-OD-16-149“  
“NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information“ 
“NOT-OD-18-212“ 
“Delayed Enforcement and Short-Term Flexibilities for Some Requirements Affecting Prospective Basic 
Science Studies Involving Human Participants“ 
“NOT-MH-14-007“ 
“NIMH Policy for Submission of Applications Containing Clinical Trials“ 
“NOT-MH-14-015“ 
“Data Sharing Expectations for NIMH-funded Clinical Trials“ 
“NOT-MH-15-012“ 
“Data Sharing Expectations for Clinical Research Funded by NIMH“ 
“NOT-MH-15-025“ 
“NIMH Policy Governing the Monitoring of Clinical Trials“ 
“NOT-MH-15-025“ 
“Policy Governing Independent Safety Monitors and Independent Data and Safety Monitoring Boards“ 
“NOT-MH-16-013“ 
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Manuscript 2: Evaluating the Impact of the 2005 National Institute of 
Mental Health Policy for the Recruitment of Participants in Clinical 
Research on Relative Citation Ratios 
 
Abstract 
Background:  The National Institutes of Health (NIH) has implemented policies to improve the rigor and 
conduct of clinical trials.  Beginning in fiscal year 2019, the NIH now requires the establishment of 
recruitment milestones and periodic reporting of recruitment progress for clinical trial grants.  While this 
policy is too recent for adequate impact evaluation, the National Institute of Mental Health (NIMH), a 
component of NIH, implemented a similar policy requiring recruitment milestones and progress 
reporting in fiscal year 2006 for NIMH-funded research.  Evaluation of the NIMH policy can provide 
insight into the likely effects of the NIH-wide policy. 
Methods:  An observational, single-group, pre/post evaluation of the association between the NIMH 
Policy for the Recruitment of Participants in Clinical Research and the Relative Citation Ratio was 
conducted for non-fellowship, competing clinical trial grants funded by the NIMH from fiscal years 2004-
2007.  The association between the recruitment policy and the mean and maximum Relative Citation 
Ratios was examined through a multiple linear regression, adjusting for total grant cost, trial target 
sample size, grantee institution size, funding mechanism, and trial design. 
Results:  124 clinical trial grants were identified.  After adjusting for covariates, the clinical trial grants 
subject to the NIMH recruitment monitoring policy were associated with a statistically significant mean-
per-grant citation ratio (citations relative to the field norm) 1.984 times that of the clinical trial grants 
that were not subject to the policy (p=0.005; 95% CI: [1.232, 3.196]).  The clinical trial grants subject to 
the policy were also associated with a non-statistically significant 1.581 times maximum-per-grant 




Conclusions:  The NIMH Recruitment Monitoring and Reporting policy was associated with a statistically 
significant increase in the mean-per-grant Relative Citation Ratio.  These NIMH-specific results suggest 
that the NIH-wide requirements for recruitment milestones and progress monitoring might also be 
positively associated with improved Relative Citation Ratio.  Increased Relative Citation Ratios generally 
reflect more impactful research. 
 
Introduction 
 The National Institutes of Health (NIH) has developed and implemented a comprehensive suite 
of policy initiatives to “ensure rigor, transparency, and effectiveness of the US federally-funded clinical 
trial enterprise” (Lauer & Wolinetz, 2016; NIH/OER, 2017).  One of these policies requires that grant 
applicants submit key information about a proposed clinical trial, including recruitment milestones, in 
the funding application and submit this application to a clinical trial-specific funding opportunity 
announcement (NIH, 2016).  Once an application has been funded, the NIH requires that funded 
researchers submit Research Performance Progress Reports to the NIH on an annual basis to track the 
conduct of clinical trials (NIH/OER, 2018).   
The Research Performance Progress Report process allows the NIH Program Officer to monitor 
the progress of the research study towards completion of the aims.  The Program Officer is the NIH staff 
member responsible for the “programmatic, scientific, and/or technical aspects of a grant” (NIH, n.d.).  
Part of this responsibility includes monitoring study enrollment progress toward the participant 
recruitment target.  Beginning in fiscal year (FY) 2019, Research Performance Progress Reports for 
clinical trials were required to report recruitment progress toward recruitment target milestones on at 
least an annual basis. Because a clinical trial is designed with a sample size that provides sufficient 
power to detect an effect of the intervention (Jones, Carley, & Harrison, 2003), failure to reach 
recruitment targets can render many trials powerless to answer the research question. 
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To avoid the consequences of under-recruitment, the NIH Program Officer (who oversees grant 
implementation) can take remediation actions to “course correct” grants that are falling behind on 
recruitment targets.  Examples of remediation actions include increased frequency of reporting (e.g., 
moving from annually to quarterly or monthly), restructuring the release of funds for expenditure (i.e., 
restricting or delaying future funds until improvement is seen), or administrative supplements 
(additional funds to address unforeseen cost increases within the scope of the funded grant).  For most 
Institutes/Centers, the default recruitment reporting period is annually.  While monitoring recruitment 
progress is a key aspect of clinical trial stewardship, it also requires additional time and effort from both 
the researcher and NIH staff.   
Because the NIH-wide policy was recently implemented, it is not yet possible to evaluate the 
impact of this policy on grant performance and research outcomes.  However, while this NIH-wide policy 
became effective in FY2019, the National Institute of Mental Health (NIMH), a component of the NIH, 
was an early adopter of a comparable policy.  In 2005, the NIMH published the NIMH Policy for the 
Recruitment of Participants in Clinical Research.  This policy mandated tracking recruitment of 
participants in clinical research studies with a planned sample size of greater than 150 participants in the 
NIMH Recruitment Milestone Reporting System as of FY2006 (NIMH, 2005).  While the NIMH policy’s 
default recruitment monitoring reporting period is triannual as compared to the NIH default of annual 
monitoring, the focus of both policies is the establishment of recruitment milestones and regular 
reporting of progress toward those milestones.  Further, the remediation options available to program 
officers are consistent under both policies.  Therefore, the NIMH recruitment monitoring policy can be 
used as a proxy to forecast the potential impact of the NIH-wide recruitment monitoring policy.   
This research examines the correlation between the implementation of the recruitment 
monitoring policy and a research outcome metric known as the Relative Citation Ratio (Hutchins, Yuan, 
Anderson, & Santangelo, 2016).  A single group pre/post evaluation was conducted to evaluate the 
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association between the policy and the Relative Citation Ratio of publications resulting from clinical trial 
grants funded by the NIMH from FY2004 through FY2007.  Given the premise that regular recruitment 
progress monitoring and remediation should improve the likelihood of successful recruitment 
completion and the notion that successful recruitment leads to sufficient statistical power to answer the 
research question, it was hypothesized that the recruitment monitoring policy will be associated with 




 The design of this study is an observational single-group pre/post evaluation of the association 
between the NIMH Policy for the Recruitment of Participants in Clinical Research and the mean-per-
grant and maximum-per-grant Relative Citation Ratios.  This policy became effective beginning with 
FY2006 grants (NIMH, 2005); therefore, the study will compare outcomes among clinical trials funded in 
FY2004 and FY2005 to outcomes among clinical trial grants funded in FY2006 and FY2007.  The primary 
outcome is a measure of research performance known as the Relative Citation Ratio or RCR (Hutchins et 
al., 2016).  It is hypothesized that the recruitment reporting policy will improve both mean and 
maximum grant Relative Citation Ratios.   
 
Study Sample 
The study sample was comprised of grants that met the following eligibility criteria: (1) new 
competing applications and competing renewals (i.e., applications seeking new years of funding for new 
aims) for non-fellowship research grants; (2) awarded by NIMH from FY2004-2007; (3) self-identified as 
clinical trials; (4) with a planned sample size of at least 150 human participants (a criterion for 
applicability of the NIMH policy of interest); and (5) had Relative Citation Ratio data available in the iCite 
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database.  Key demographics and grant performance outcomes were collected for each grant in the 
sample.  These data were analyzed for a relationship between the implementation of the recruitment 
monitoring policy and the grant performance outcome measure. 
Clinical trial grants were identified using the NIH’s IMPAC II database using the Query View 
Report search interface.  Grant characteristics were identified using the IMPAC II database and Research 
Portfolio Online Reporting Tools (NIH, 2019).  The Relative Citation Ratio was identified from the NIH 
Office of Portfolio Analysis’s iCite tool (NIH/OPA, 2016). 
 
Measures 
The independent variable (the NIMH recruitment policy) became effective at the beginning of 
FY2006.  Grants applications were subject to the policy if initially awarded in FY2006 or later.  The 
dependent variable (Relative Citation Ratio) was obtained for the sample of grants described.  The 
Relative Citation Ratio (RCR) is “a field-normalized metric that shows the scientific influence of one or 
more articles relative to the average NIH-funded paper” (NIH/OPA, 2016).  More simply stated, the 
metric is a ratio of the number of citations/year for a publication or group of publications compared to 
the average number of citations/year for all publications in that field of research.  A ratio of “1” indicates 
that the publication(s) was cited with the same frequency as other publications in the field.  A value of 
greater than 1 indicates that the publication was more highly cited than others in the field (ergo it is 
more “influential” than other publications by the field).  Because most grants will result in multiple 
publications, two versions of the Relative Citation Ratio were used.  The first outcome, mean RCR, is the 
average Relative Citation Ratio of all publications resulting from the grant.  The second outcome, 
maximum RCR, is the highest single Relative Citation Ratio value from any single publication resulting 
from the grant.  Both outcomes yield valuable information.  The mean RCR demonstrates total grant 
productivity across all publications, but it may dilute the impact of the primary publication with less-
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impactful secondary publications or protocol publications.  The maximum RCR will show the impact of 
the single most prominent publication from a grant.  This is likely to be the publication associated with 
the primary outcome analysis.   
The analyses controlled for the following variables as potential confounders: total grant cost, 
trial target sample size, grantee institution size, funding mechanism, and trial design.  Total grant cost 
and trial target sample size were continuous numeric variables.  Grantee institution size was defined as 
the size of the research portfolio at a given research organization.  Each organization was labeled 
categorically as either less than x<$200,000,000 USD, $200,000,000 ≤ x < $400,000,000, or x ≥ 
$400,000,000 USD in total FY2006 NIH funding.  Funding mechanism was a categorical variable that 
represented the different types of grant mechanisms (e.g., R01, U01, or U10).  Trial design, also a 
categorical variable, represented study design types such as randomized controlled trial, cluster 
randomized controlled trial, and pre/post trial. 
 
Data Abstraction 
Sample Identification and Abstraction 
The clinical trial grants were identified through a Query View Report search of the internal NIH 
IMPAC II grant database.  The database was searched for NIMH grants competitively funded from 
FY2004-2007 with the word “trial” in the text of the grant application title, abstract, or aims.  This 
information was exported to a Microsoft Excel spreadsheet.  Fellowship awards were excluded from the 
sample.  Each grant was then manually reviewed to determine whether it was self-identified by the 
applicant as a clinical trial.  If not, the record was excluded.  Next, each grant was reviewed to determine 
the planned sample size.  Proposals with fewer than 150 subjects were not covered by the NIMH policy 




Covariate Identification and Abstraction 
Each grant application was reviewed to determine the clinical trial design and planned sample 
size.  The Query View Report search results also returned the total grant award cost, grantee institution 
name, fiscal year, and funding mechanism for the identified sample of clinical trials.  Grantee institution 
size was determined cross-referencing the grantee institution name with the total NIH funding in FY2006 
identified in the NIH Research portfolio Online Reporting Tool (https://report.nih.gov/award/index.cfm).   
 
Outcome Identification and Abstraction 
 The mean and maximum Relative Citation Ratio values were identified by searching the grant 
number in the iCite database (NIH/OPA, 2016).  The mean RCR for all publications and the highest RCR 
for any publication associated with each grant was recorded in the excel spreadsheet.  If no publication 
information was available, the grant was excluded from the sample. 
 
Analysis 
A multiple linear regression was conducted to evaluate the association between the recruitment 
reporting policy and the mean Relative Citation Ratio for each grant.  A second multiple linear regression 
was conducted to examine the association of the recruitment reporting policy with the maximum 
Relative Citation Ratio for each grant.  The Relative Citation Ratios were log-transformed to establish a 
normal distribution.  The relationship between the policy and Relative Citation Ratio was adjusted for 
fiscal year, total grant award cost, grantee institution size, trial target sample size, funding mechanism, 







 A number of limitations to this study exist and warrant further exploration.  First, this study was 
designed to examine correlation and does not prove a causal pathway.  Second, the study did not 
examine the degree to which individual clinical trial grants complied with the policy nor did it assess the 
extent to which recruitment milestones (or the planned enrollment goals) were met.  Third, this study 
examined only NIMH-funded clinical trials with a planned sample size of at least 150 participants.  
Fourth, the study did not account for historically high/low performing researchers/research teams.  
Fifth, this study did not evaluate the impact of trial outcomes (i.e., positive versus negative findings) on 
relative citation ratio. 
 
Results 
 The study sample selection process is outlined in Figure 1.  Of the 4,388 NIMH-funded 
competitive research grants funded from FY2004-2007, 487 mentioned the word “trial” in the title, 
abstract, or aims.  Thirteen of these grants were fellowships and 474 were non-fellowship grants.  267 
grants self-identified the study as a clinical trial in the grant application.  134 of those grants had a 
planned sample size of at least 150 human subjects.  Ten grants did not have publications properly 
linked to the grant number.  This is a limitation of the data.  Individual publications and/or references to 
manuscripts were found for eight of those ten grants, but inclusion of the relative citation ratio 
outcomes for only the papers found by manual identification would have introduced bias; therefore, 
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 The clinical trial sample demographics are displayed by fiscal year in Table 1.  Between 26 and 
40 clinical trials with planned sample sizes of at least 150 participants were funded each year.  The most 
frequent clinical trial design, by far, was an individually-randomized controlled trial design (110 out of 
124).  Twelve of the remaining trials were cluster-randomized controlled trials and two were pre/post 
trials.  Pre/post (or pre-post) trials are prospective intervention studies without a control group (Thiese, 
2014).  Similarly, a research grant mechanism (e.g., R01, R34, etc.) was the most frequent mechanism 
with 95 of 124 trials in the sample.  Cooperative agreements, or U-mechanisms, were the next most 
common with 26 of 124 trials.  Across the four fiscal years, the mid-size and larger grantees received 70 
of the 124 trials.  The planned sample sizes ranged from 150 participants to 5,920 participants with a 
mean of 485.  The mean sample size per fiscal year is also displayed in table 1. 
 The maximum Relative Citation Ratio, or the highest RCR for any single publication associated 
for a grant, ranged between 0.32 and 47.76 with a mean of 7.78.  As noted previously, a value of less 
than 1 indicates that the publication was less-cited than the average publication in that field.  The mean 
and range of the single-publication maximum values are displayed by fiscal year in table 1.  For all 




Table 1. Sample Demographics by Fiscal Year 
Fiscal Year 2004 2005 2006 2007 
n  28 26 40 30 
Clinical Trial Design     
  Cluster RCT 6 1 3 2 
  Pre/Post 1 1 0 0 
  RCT 21 24 37 28 
       
Funding Mechanism     
  Career Development Awards (K) 1 2 0 0 
  Research Grants (R) 22 20 25 28 
  Cooperative Agreements (U) 5 4 15 2 
       
Grantee size     
  x<$200,000,000 USD 8 11 19 16 
 $200,000,000≤x<$400,000,000 USD 7 9 7 7 
  x≥$400,000,000 USD 13 6 14 7 
       
Maximum Relative Citation Ratio     
  Mean 8.53 8.55 7.06 6.84 
  Range 1.40 - 47.46 0.62 - 41.06 0.32 - 34.81 0.54 - 45.48 
       
Mean Relative Citation Ratio     
  Mean 1.96 2.14 2.87 1.74 
  Range 0.79 - 5.30 0.46 - 5.05 0.32 - 5.86 0.45 - 3.77 
       
Average Total Award Cost $ 2,583,064 $ 2,258,076 $ 1,902,647 $ 2,822,873 
       




The mean RCR and maximum RCR values were analyzed and determined to be non-normally 
distributed by histogram, Shapiro-Wilk test, and Q-Q plot.  The mean and maximum RCR values were 
log-transformed to establish a normal distribution.  The log-transformed distribution of mean RCR and 
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maximum RCR was confirmed as normal with the Shapiro-Wilk test, kernel density plot of studentized 
residuals, and Q-Q plot.  No severe outliers were identified.  Following multiple linear regression, the 
coefficients and confidence intervals were exponentiated and displayed in Table 2. 
 
Mean RCR Regression 
A multiple linear regression was performed to investigate whether the implementation of the 
recruitment monitoring policy could significantly predict the average Relative Citation Ratio of 
publications associated with a given clinical trial grant.  The results of the regression indicated that the 
model explained 23.3% of the variance and that the model was a significant predictor of mean Relative 
Citation Ratio.  The implementation of the recruitment milestone reporting policy was associated with a 
1.984 increase in mean per-grant Relative Citation Ratio (p=0.005; 95% CI: [1.232, 3.196]) when 
adjusting for grantee size, total grant award cost, planned sample size, fiscal year, funding mechanism, 
and clinical trial design.  Fiscal year and the R43 funding mechanism were also positively associated with 
mean RCR.  The reference case for funding mechanism was the R01 mechanism.  Grantee size, total 
award cost, planned sample size, and clinical trial design did not have statistically significant associations 
with mean RCR. 
 
Maximum RCR Regression 
A second multiple linear regression was performed to investigate whether the implementation 
of the recruitment monitoring policy could significantly predict the maximum Relative Citation Ratio of 
any publication associated with a given clinical trial grant.  The results of the regression indicated that 
the model explained 16.7% of the variance but the model itself was not a significant predictor of 
maximum Relative Citation Ratio at the α=0.05 level (p=0.1423). Under this model, the implementation 
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of the recruitment milestone reporting policy was associated with a 1.581 increase in the maximum per-
grant Relative Citation Ratio (p=0.246; 95% CI: [0.726, 3.440]) when adjusting for grantee size, total 
grant award cost, planned sample size, fiscal year, funding mechanism, and clinical trial design.  The R43 
funding mechanism was positively associated with an increased maximum Relative Citation Ratio as 




Table 2. Results of Multiple Linear Regression Analyses for Mean Grant and Maximum Grant 
Relative Citation Ratios   
  
Mean Grant Relative Citation 
Ratioa 
Maximum Grant Relative Citation 
Ratiob 
  β P value 
[95% 
Confidence 
Interval] β P value 
[95% Confidence 
Interval] 
            
Recruitment Policy1 1.984 0.005** 1.232 3.196 1.581 0.246 0.726 3.440 
Grantee Size2           
  x<$200,000,000USD REF REF REF REF REF REF REF REF 
  $200,000,000USD≤x<$400,000,000 1.000 0.998 0.767 1.304 1.051 0.821 0.682 1.618 
  x≥$400,000,000USD 0.884 0.340 0.686 1.140 0.909 0.650 0.601 1.376 
Total Award Cost 1.000 0.361 1.000 1.000 1.000 0.403 1.000 1.000 
Planned Sample Size 1.000 0.360 1.000 1.000 1.000 0.896 1.000 1.000 
Fiscal Year 0.738 0.006** 0.595 0.917 0.753 0.114 0.529 1.072 
Funding Mechanism3           
    R01 REF REF REF REF REF REF REF REF 
    K (Career Development) 1.625 0.203 0.767 3.442 2.665 0.115 0.784 9.063 
    R15 0.843 0.698 0.353 2.014 0.443 0.258 0.107 1.831 
    R21 0.471 0.206 0.146 1.522 0.257 0.162 0.038 1.740 
    R34 1.667 0.053 0.993 2.799 0.867 0.739 0.373 2.019 
    R43 0.158 0.002** 0.049 0.512 0.061 0.005** 0.009 0.414 
    U01 1.208 0.290 0.849 1.720 0.890 0.689 0.500 1.582 
    U10 0.564 0.104 0.282 1.127 0.777 0.659 0.251 2.402 
Clinical Trial Design           
    RCT3 REF REF REF REF REF REF REF REF 
    Cluster RCT4 0.831 0.441 0.518 1.334 0.807 0.584 0.373 1.746 
    Pre/Post Trial 0.583 0.229 0.241 1.410 0.292 0.093 0.069 1.233 
aMean Relative Citation Ratio of all publications for each grant 
bHighest Relative Citation Ratio of any publication for each grant 
1NIMH Recruitment Milestone Reporting Policy; 2Grantee's total NIH funding in FY2006; 





This study investigated the association between a NIMH policy requiring the establishment of 
recruitment milestones and progress reporting with grant performance outcomes.  The hypothesis was 
that the implementation of this recruitment policy would be correlated with improved clinical trial grant 
performance as demonstrated by an increase in mean and maximum Relative Citation Ratios.  This 
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hypothesis was based upon three logical assumptions: (1) establishing recruitment milestones and 
monitoring progress toward said milestones would increase the likelihood of reaching those milestones, 
(2) studies that reach their recruitment targets are more likely to have statistical power to test their 
research hypothesis, and (3) research adequate statistical power is more valued by fellow researchers 
than underpowered research.  Findings from this study suggest a positive association between the 
implementation of the recruitment monitoring and reporting policy and both the mean and maximum 
Relative Citation Ratio; however, only the positive association with the mean Relative Citation Ratio was 
statistically significant.   
The finding that the recruitment monitoring policy was associated with an increase in mean 
relative citation ratio suggests that the scientific community found the publications resulting from the 
trials covered by the recruitment monitoring policy to be, on average, more valuable (and therefore 
worth referencing) than those not covered by the policy.  As previously mentioned, studies that under-
recruit are less likely to have statistical power to answer their research questions.  If we assume that 
enhanced attention to recruitment increases the likelihood of sufficient recruitment, then the higher 
mean RCR may illustrate that these trials achieved statistical power to answer the research questions 
and publish results.  
 Unlike the mean RCR association, the positive association between the recruitment policy and 
the maximum RCR was not statistically significant.  If the mean RCR represents the influence of all 
publications from the grant as a whole, then the maximum RCR can be understood as a measure of the 
single most influential publication from with each clinical trial grant.  The non-significant finding 
suggests that, while the policy may be associated with more influential research, the single-most 
influential publication may be correlated to something other than the policy.  One possibility includes 
bias toward publication and citation of positive results.  Previous research has shown that positive 
outcomes are more likely to be cited than negative outcomes; therefore, the maximum RCR per grant 
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may be influenced by whether the study findings were positive (de Vries et al., 2018; Duyx, Urlings, 
Swaen, Bouter, & Zeegers, 2017; Jannot, Agoritsas, Gayet-Ageron, & Perneger, 2013).  Positive versus 
negative trial outcomes were not accounted or adjusted for in this analysis and should be investigated 
further.  
 The initial premise for examining this relationship was not just to identify the association 
between the NIMH recruitment monitoring policy and the impact on NIMH clinical trial grant outcomes.  
While this is useful information for the NIMH as a funding agency, the broader goal was to forecast the 
impact of the FY2019 NIH-wide policy that requires establishment of recruitment milestones and 
periodic (at least annual) reporting of recruitment progress.  In this study, the NIMH policy was viewed 
as a proxy for the subsequent NIH-wide policy.  The NIMH policy requires the establishment of 
recruitment milestones and triannual reporting on progress toward those milestones.  The NIH policy 
requires at least annual milestones and recruitment progress reporting (with the option for NIH staff to 
choose more frequent time intervals).  Both policies establish a premise of target milestones and 
periodic reporting of progress toward those targets.  If we accept that the NIMH and NIH policies are 
similar, then we can infer that the results of this study suggest a positive association would be observed 
between the implementation of the FY2019 NIH-wide policy and the mean Relative Citation Ratio (and 
discount the notion that the administrative burden of regular recruitment monitoring is harmful to 
research progress).  Further studies are recommended to examine the impact of compliance on the 
association, the association with smaller clinical trials, and the association for trials in other scientific 
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Manuscript 3: Evaluating the Impact of the Revised National Institutes of 
Health Clinical Trial Definition on Recruitment Progress 
 
Abstract 
Background:  The National Institutes of Health (NIH) announced a revised definition of “clinical trial” in 
2014 to improve trial identification and administrative compliance.  Researchers and professional groups 
have voiced concerns that the revised definition will add administrative burden that will slow research 
progress.  The National Institute of Mental Health (NIMH), a component of NIH, began systematically 
identifying and tracking grants that met the revised clinical trial definition in 2015 (four years prior to 
the development of an NIH-wide system in 2019).  Evaluation of the policy’s effect on recruitment 
progress in NIMH-funded grants may forecast the NIH-wide effect. 
Methods:  A quasi-experimental study examined the effect of the new clinical trial definition policy on 
recruitment progress in grants.  The study used a difference-in-differences design comparing 
recruitment progress before and after the policy took effect in a group of studies newly identified as 
clinical trials under the policy relative to a comparison group of clinical trials unaffected by the new 
policy.  The primary outcome was a measure of on-pace recruitment progress toward milestone targets.  
The relationship between the policy and recruitment progress was examined through a multiple logistic 
regression, adjusting for fiscal year, NIMH funding division, grant funding, ClinicalTrials.gov registration, 
trial sample size, and total NIH funding awarded to a grantee institution.  
Results:  A total of 132 clinical trial grants were identified and analyzed.  There were 90 grants in the 
intervention group and 42 grants in the control group.  Within the intervention group, 52 grants were 
impacted by the revised definition policy.  After adjusting for covariates, the difference-in-differences in 
recruitment progress before and after the policy change between the control and intervention groups 
was not significant.  Trials led by researchers at institutions receiving more than $400,000,000 in funding 
from NIH had significantly higher odds of meeting recruitment targets (OR: 4.95; 95% CI: 1.63-15.01).  
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Conclusions:  The NIH revised clinical trial definition had no clear effect on recruitment progress in 
newly-identified NIMH-funded clinical trials as compared to traditionally-identified clinical trials.  
Therefore, this study did not find evidence supporting the concern that revised clinical trial definition 
would delay research progress.  Further research is needed to evaluate other implications of the policy. 
 
Introduction 
In late October 2014, the National Institutes of Health (NIH) announced a policy revising the 
definition of “clinical trial” as the beginning of an effort to ensure that all clinical trials are correctly 
identified, properly conducted, and that the results are reported promptly to share the knowledge 
gained with the public (Hudson, Lauer, & Collins, 2016).  The previous definition used by NIH was “a 
prospective biomedical or behavioral research study of human subjects that is designed to answer 
specific questions about biomedical or behavioral interventions (drugs, treatments, devices, or new 
ways of using known drugs, treatments, or devices)” (Reif-Lehrer, 2005).  The prior definition was 
considered vague; therefore, the NIH revised the definition to “a research study in which one or more 
human subjects are prospectively assigned to one or more interventions (which may include placebo or 
other control) to evaluate the effects of those interventions on health-related biomedical or behavioral 
outcomes” (NIH, 2014).  The revised definition is consistent with the definitions issued by the World 
Health Organization, International Committee of Medical Journal Editors (ICMJE), and other United 
States governmental research agencies (DHHS, 2017; ICMJE, n.d.; WHO, n.d.); however, the NIH also 
uses this definition in other policies to determine the applicability of numerous administrative 
requirements such as good clinical practice training and ClinicalTrials.gov registration and results 
reporting (APS, 2017, 2018; Kaiser, 2017).  This revision also expanded the range of studies that are 
classified as a clinical trial. 
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  The revised definition policy was met with resistance from researchers in the basic behavioral 
and social science fields who felt the expansion would force unnecessary compliance burdens on their 
studies including clinical trial registration, results reporting, and a “massive amount of dysfunction and 
paperwork” (Kaiser, 2017).  The concerns were that the associated clinical trial policies are onerous and 
impose biomedical clinical research standards on non-biomedical study designs (FABBS, 2017; Kaiser, 
2017).  While general agreement exists on NIH’s overall goals of better science, those opposed to the 
policy changes warned that burdensome or incongruous requirements would slow or even halt the 
progress of science (NIH, 2016). 
The NIH clinical trial definition has been a subject of much debate over the last three years.  To 
date, the arguments (for and against) the revised definition have been made on anecdotal experiences 
of researchers, regulators, funders, policy makers, and the general public.  No formal evaluation has 
been conducted on the impact of this policy change on grant progress.  To evaluate whether 
administrative burden of clinical trial policies based on the revised clinical trial definition delayed grant 
progress, this study examined the relationship between the clinical trial definition policy and study 
recruitment progress.  Potential delays in study startup and conduct can be identified by examining the 
progress of study recruitment toward a priori milestones. 
Although the revised definition was announced in 2014 and effective for NIH-funded research 
beginning in fiscal year (FY) 2016, many NIH Institutes/Centers did not have the capacity to identify and 
track all clinical trials (using the revised definition) until an NIH-wide system was implemented in 
FY2019.  However, the National Institute of Mental Health (NIMH), an institute within of the NIH, 
identified grants that met the revised clinical trial definition and tracked these grants through an 
internally developed software application beginning with grants funded in FY2015 (one year prior to the 
policy effective date).  The NIMH also funds basic behavioral researcher.  Basic behavioral researchers 
were among the forefront of those who expressed concerns with the potential burdens of the revised 
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definition on their research (FABBS, 2017).  Therefore, the impact of the revised clinical trial definition 
implementation on the progress of NIMH-funded grants can be used to forecast the potential impact 




 This quasi-experimental study uses a difference-in-differences design to evaluate the effect of 
the revised NIH clinical trial definition policy on research participant recruitment progress in NIMH-
funded clinical trial grants from FY2015-2017.  This study examines the difference in effect before and 
after the policy implementation for clinical trial grants that would have been defined by NIMH as clinical 
trials both before and after the new policy was implemented  (control group) versus a set of studies that 
would not have been deemed clinical trials in the pre-policy period but were identified as clinical trials 
under the new policy (intervention group).  The revised clinical trial definition policy became effective 
beginning with FY2016 grants (NIH, 2014); therefore, this study compares the difference in recruitment 
progress for clinical trials initially funded from FY2015-2017, with grants funded in FY2015 not subject to 
the new clinical trial definition policy and grants funded in FY2016 and FY2017 subject to the policy.  The 
primary outcome is a binary measure of whether or not the 20-month recruitment milestone was met.  
The overall hypothesis is that this policy is not harmful to recruitment progress; therefore this study will 
test the null hypothesis that the revised clinical trial definition policy will have no effect on the 
difference-in-differences for recruitment progress before and after the policy took effect in a group of 
studies newly identified as clinical trials under the policy relative to a comparison group of clinical trials 
unaffected by the new policy.  Recruitment progress delays would be demonstrated by a significant 





The study sample was comprised of grants that met the following eligibility criteria: (1) new 
competing applications and competing renewals (i.e., applications seeking new years of funding for new 
aims) for non-fellowship; (2) non-HIV/AIDS research grants; (3) awarded by NIMH from FY2015-2017; (4) 
NIH-defined clinical trials (using the revised definition); and (5) with recruitment progress data available 
in the NIMH Recruitment Milestone Reporting database.  “Delayed onset” trials (i.e., trials that do not 
begin until year 2-3 of a grant by intentional design) were excluded because they would not have 
comparable recruitment progress data.   
Clinical trial grants were allocated to the control arm if the funding application was submitted 
and funded through a NIMH Clinical Trial Funding Opportunity Announcement (FOA).  The NIMH Clinical 
Trial FOAs outlined the types of clinical trials accepted by NIMH through the experimental therapeutics 
paradigm established prior to the implementation of the revised policy (Insel & Gogtay, 2014; NIMH, 
n.d.).  These announcements were exclusively reserved for trials designed to “establish the safety, 
clinical efficacy, effectiveness, clinical management and/or implementation of preventive, therapeutic, 
or therapeutic interventions.” These FOAs were mandatory for any trial design toward those goals. 
These trials were included in the control arm because they would have been deemed clinical trials 
before and after the new clinical trial definition policy went into effect in FY2016; the policy did not 
affect this sub-set of trials.   
The intervention group consists of all clinical trials funded by NIMH in FY2015-17 that were (or 
would have been) considered a clinical trial under the revised definition but were not counted under the 
previous definition.  Non-traditional clinical trials, such as mechanistic trials and BESH trials, are not 
accepted under the NIMH clinical trial funding announcements because they do not follow the 
experimental therapeutics approach.  Clinical trial grants that were not submitted under the NIMH 
Clinical Trial FOAs were allocated to the intervention arm; this subset of trials would not have been 
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deemed clinical trials in the pre-policy period but were defined as clinical trials under the new policy.  
The intervention arm also captures “traditional” clinical trials that should have been submitted through 
the NIMH Clinical Trial FOAs but were not identified or peer-reviewed as clinical trials under the old 
definition.   
 
Measures 
The dependent variable in this analysis was recruitment performance.  Acceptable recruitment 
performance was defined by the actual recruitment progress meeting or exceeding the target 
recruitment at the fifth triannual reporting window (approximately 20 months).  Sensitivity analyses 
were conducted using varying thresholds to define acceptable recruitment progress (i.e., 95%, 90%, and 
80% of target).  The independent variable was the NIH clinical trial definition policy.  Potential 
confounders controlled for in the analyses were initial fiscal year of funding, NIMH funding division, total 
grant funds requested, ClinicalTrials.gov registration, planned trial sample size, and total amount of NIH 
funding to the grantee institution.   
 
Data Collection 
Sample Identification and Abstraction 
Clinical trial grants were identified from the NIMH Clinical Trial Operations Software database.  
The NIMH Clinical Trial Operations Software database was queried for all studies meeting the 
intervention and control group criteria described above and initially funded FY2015-2017.  This was 
possible because the NIMH had previously identified and recorded the FY2015 (pre-policy change) 
grants that would have been deemed clinical trials under the new definition.   
Figure 1 illustrates the sample selection process.  The 296 non-HIV/AIDS NIMH-funded grants 
were downloaded to a Microsoft Excel spreadsheet.  HIV/AIDS grants were excluded because the NIMH 
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was considering a reorganization of these programs at that time and the relevant data were therefore 
not collected.  The initial fiscal year of funding and NIMH funding division for each grant were also 
abstracted from this system.  The results were manually cross-referenced with the NIMH Recruitment 
Milestone Reporting database to identify which clinical trials had triannual recruitment reporting data.  
164 grants did not report triannual recruitment data or did not have recruitment reporting data 
available at the 20-month timepoint and were excluded from this analysis.  Possible reasons for the 
absence of recruitment data in the NIMH Recruitment Milestone Reporting database include planned 
delayed onset trials (trial not scheduled to begin in the first grant year) and smaller grants (reporting 
was not mandatory for clinical trials with sample sizes of less than 150 participants prior to FY2017).  The 
remaining 132 studies comprised the sample for this study.  The grant applications for these studies 
were reviewed in the NIH IMPAC II database to identify the funding opportunity announcement to 
which the grant application was submitted.  Applications submitted to a NIMH Clinical Trial FOA were 
allocated to the control arm.  Grant applications that met the revised NIH clinical trial definition but 
were submitted to any non-clinical trial FOA were allocated to the intervention arm. 
 
Outcome Identification and Abstraction 
 The NIMH Recruitment Milestone Reporting database was queried for recruitment data for each 
study.  The original recruitment milestone target and actual reported recruitment numbers were 
recorded for the fifth triannual reporting window (approximately 20 months from recruitment 
initiation).  These data were used to determine whether the study was meeting recruitment goals at 20 






Covariate Identification and Abstraction 
As previously noted, the initial fiscal year of funding and NIMH funding division were abstracted 
as categorical variables from the Clinical Trial Operations Software database during the clinical trial 
sample abstraction.  The initial fiscal year of funding was used to identify the applicability of the clinical 
trial definition policy (“Policy Intervention”).  The policy did not apply to FY2015 grants and did apply to 
FY2016 and FY2017 grants.  Using the NIH IMPAC II database, each grant was manually reviewed to 
abstract the total funding requested, the grantee institution name, and whether the study was 
registered in ClinicalTrials.gov ("ClinicalTrials.gov Registration").  Grantee Institution Size was 
determined by manually cross-referencing the grantee institution name with the total NIH funding in 
FY2016 identified in the NIH Research portfolio Online Reporting Tool 
(https://report.nih.gov/award/index.cfm) and coded as an ordinal categorical variable (in increments of 
$100M USD in FY16).  The Planned Trial Sample Size was abstracted from the NIMH Recruitment 
Milestone Reporting database by searching for each clinical trial grant number. 
 
Analysis 
Sample characteristics were analyzed by group (intervention and control).  The associations 
between covariates and group were analyzed using Fisher's exact test and the Student's t-tests.  Two 
multiple logistic regressions were performed to examine the effect of the policy on recruitment progress 
for each group.  Then, a multiple logistic regression calculating the difference in pre/post policy change 
in recruitment progress in the intervention versus control groups (the difference-in-differences) was 
conducted via the following model: 
Y = β0 + β1*[Group] + β2*[Policy Intervention] + β3*[Difference-in-Differences] + β4*[Fiscal Year] 
+ β5*[NIMH Division] + β6*[Total Grant Funds Requested] + β7*[ClinicalTrials.gov Registered] + 




The Difference-in-Differences variable was calculated using Group*Policy Intervention; 
therefore, the coefficient for this variable represents only those grants that were reclassified by the 
definition change after the policy went into effect.  The model fit was validated using Pearson's 
goodness-of-fit test (p=0.244) and the Hosmer-Lemeshow statistic (p=0.596) which did not indicate that 
the predicted probabilities deviate from the observed probabilities in a way that the binomial 
distribution does not predict (Minitab, 2019).  These analyses were conducted using Stata/IC Version 
14.2 (StataCorp, 2015). 
 
Results 
 From 2015-2017, the NIMH funded 367 grants that met the new NIH definition of clinical trial.  
296 of these were non-HIV/AIDS research.  144 of these trials did not have recruitment data available in 
the NIMH Recruitment Milestone Reporting system.  The primary reason for data not being available is 
that the NIMH Recruitment Milestone Reporting system only captured trials with a planned sample size 
of greater than 150 participants before FY2017.  119 (83%) of these excluded grants were funded in 
FY2015 and FY2016 prior to that change.  Fellowship awards comprised an additional 10 (6.9%) of these 
excluded grants.  Fellowships were exempt and can no longer contain clinical trials under NIH policy.  
Many of the excluded grants were also designed as shorter length grants, such as an R03 mechanism, 
with 48 (33.3%) having 2 years or less years of funding and 70 (48.6%) having three years or less.  Of the 
144 grants that did not report recruitment data, 18 (12.5%) were funded by the Division of Neuroscience 
and Basic Behavioral Science, 89 (61.8%) by the Division of Translational Research, 29 (20.1%) by the 
Division of Services and Intervention Research, and 8 (5.5%) by the Office of the NIMH Director.   
Of the remaining 152 trials, 20 were excluded because recruitment had not (or would not) reach 
the fifth triannual recruitment window.  Reasons for not reaching the window included delayed-onset 
trials or early closure of the grant.  No instances of early closure were observed as resulting from 
insufficient recruitment.  The remaining 132 clinical trial grants constituted the sample for this analysis. 
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 The sample demographics and statistical association between covariates are displayed by group 
in Table 1.  In total, 42 grant applications were in the control group and 90 were in the intervention 
group.  In the control group, 36% of trials were meeting or exceeding recruitment goals while 43% were 
meeting or exceeding recruitment goals in the intervention group.  Of the 90 grants in the intervention 
group, 38 were funded in FY2015 prior to the definition change while 52 were funded in FY2016-2017 
after the policy was effective.  The association between initial fiscal year of funding and group was 
statistically significant.  The average funding requested was nearly equal between groups while the 
average planned sample size was notably lower for the intervention group.  Neither of these 
associations were statistically significant.  The majority of clinical trials were funded through the NIMH’s 
Division of Services and Intervention Research and the Division of Translational Research.  The 
association between funding division and group was statistically significant.  The R01 funding 
mechanism was the most frequently used funding mechanism for both groups.  The rate of 
ClinicalTrials.gov registration was comparatively 66% higher in the control group relative to the 
intervention group and the association was statistically significant.   Of the 52 grants funded in FY2016-
17 that were considered clinical trials due to this policy, 69% have registered in ClinicalTrials.gov.  Clear 
differences were observed based upon the type of clinical trial.  Only 12.5% (1) of the basic science 
studies considered clinical trials due to this policy clinical trials were registered while 55% (6) of 
mechanistic clinical trials and 85% (27) of randomized clinical trials were registered.  The association 
between funding mechanism and group was statistically significant.  The association between 
intervention type and group was statistically significant.  The association between grantee institution 
size and group was not statistically significant.    
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n (%)    42 90  
Initial Fiscal Year of Funding   0.045 
  2015 10 (23.8%) 38 (42.2%)  
  2016 6 (14.3%) 17 (18.9%)  
  2017 26 (61.9%) 35 (38.9%)  
Average Total Requested Funding $ 2,739,379 $ 2,732,130 0.065 
Funding Division   0.020 
  Office of the NIMH Director 0 (0%) 4 (4.4%)  
  Division of Neuroscience and Basic Behavioral Science 0 (0%) 3 (3.3%)  
  Division of Services and Intervention Research 23 (54.8%) 26 (28.9%)  
  Division of Translational Research 19 (45.2%) 57 (63.3%)  
Funding Mechanism   <0.001 
  Career Development Awards (K) 0 (0%) 8 (8.9%)  
  Program Project Grants/Center Grants (P) 0 (0%) 3 (3.3%)  
  Cooperative Agreements (U) 1 (2.4%) 4 (4.4%)  
  R01 18 (42.9%) 58 (64.4%)  
  R34 8 (19.0%) 3 (3.3%)  
  R61/R33 12 (28.6%) 0 (0%)  
  Other Research Grants (R) 3 (7.1%) 14 (15.6%)  
Average Planned Trial Sample Size 605 355 0.326 
Design Type   <0.001 
  Basic Science Clinical Trial 0 (0%) 20 (22.2%)  
  Group Randomized Controlled Trial 2 2 (2.2%)  
  Mechanistic Clinical Trial 0 (0%) 26 (28.9%)  
  Individually Randomized Controlled Trial 39 36 (40.0%)  
  Other 1 6 (6.7%)  
Intervention Type   <0.01 
  Behavioral 31 (73.8%) 39 (43.3%)  
  Device 6 (14.3%) 19 (21.1%)  
  Drug 5 (11.9%) 14 (15.6%)  
  Surgical 0 (0%) 1 (1.1%)  
  Other 0 (0%) 17 (18.9%)  
ClinicalTrials.gov Registration Reported to NIMH 90.5% 54.4% <0.001 
Grantee Institution Size (in FY2016 NIH Funding)   0.678 
  X <$100,000,000 USD 13 (31.0%) 38 (42.2%)  
  $100,000,000 ≤ X < $200,000,000 12 (28.6%) 18 (20.0%)  
  $200,000,000 ≤ X < $300,000,000 5 (11.9%) 8 (8.9%)  
  $300,000,000 ≤ X < $400,000,000 2 (4.8%) 4 (4.4%)  





Multiple logistic regressions were performed to identify the association between the policy and 
recruitment performance for each group.  As shown in Table 2, the multiple logistic regression model 
(p=0.52) for the control group did not find a significant association between the policy and on-target 
recruitment progress with an odds ratio of 2.44 [p=0.70; 95% CI: 0.03, 227.71].  Similarly, as shown in 
Table 3, the multiple logistic regression model (p<0.001) for the intervention group did not find a 
statistically significant association between the policy and on-target recruitment progress with an odds 
ratio of 4.05 [p=0.33; 95% CI: 0.24, 68.42].   





Error z P>|z| 
[95% Confidence 
Interval] 
         
Policy Intervention 2.44 5.65 0.39 0.70 0.03 227.71 
Initial Fiscal Year of Funding 0.46 0.56 -0.64 0.53 0.04 5.11 
NIMH Division        
  Division of Translational Research REF REF REF REF REF REF 
  Division of Services and Intervention Research 0.79 0.62 -0.31 0.76 0.17 3.66 
Total Grant Funds Requested 1.00 0.01 0.15 0.88 0.98 1.03 
ClinicalTrials.gov Registered 1.10 1.66 0.07 0.95 0.06 21.02 
Planned Trial Sample Size 1.00 0.00 -0.62 0.54 1.00 1.00 
Grantee Institution Size        
  X <$100,000,000 USD        
  $100,000,000 ≤ X < $200,000,000 7.07 7.43 1.86 0.06 0.90 55.52 
  $200,000,000 ≤ X < $300,000,000 1.00 - - - - - 
  $300,000,000 ≤ X < $400,000,000 6.69 11.47 1.11 0.27 0.23 193.04 












Error z P>|z| 
[95% Confidence 
Interval] 
         
Policy Intervention 4.05 5.84 0.97 0.33 0.24 68.42 
Initial Fiscal Year of Funding 0.17 0.14 -2.11 0.04 0.03 0.88 
NIMH Division        
  Division of Translational Research REF REF REF REF REF REF 
  Office of the NIMH Director 1.07 1.28 0.05 0.96 0.10 11.13 
  Division of Neuroscience and Basic Behavioral Science 4.26 6.60 0.94 0.35 0.20 88.78 
  Division of Services and Intervention Research 0.83 0.62 -0.25 0.81 0.19 3.58 
         
Total Grant Funds Requested 0.99 0.01 -0.84 0.40 0.98 1.01 
ClinicalTrials.gov Registered 0.47 0.32 -1.09 0.28 0.12 1.81 
Planned Trial Sample Size 1.00 0.00 -1.96 0.05 0.99 1.00 
Grantee Institution Size        
  X <$100,000,000 USD REF REF REF REF REF REF 
  $100,000,000 ≤ X < $200,000,000 0.35 0.27 -1.36 0.17 0.08 1.59 
  $200,000,000 ≤ X < $300,000,000 0.49 0.48 -0.74 0.46 0.07 3.30 
  $300,000,000 ≤ X < $400,000,000 5.09 6.67 1.24 0.22 0.39 66.42 
  $400,000,000 < X 4.48 3.25 2.07 0.04 1.08 18.59 
 
To examine the effect of the clinical trial definition policy on the recruitment progress outcome 
in the intervention group relative to the control group, a difference-in-differences multiple logistic 
regression was performed.  The results of this difference-in-differences analysis are displayed in Table 4.  
This multiple logistic regression model has a chi-squared probability <0.01 and explains 19.9% of the 
variance (R2).  The difference-in-differences between the grants affected by the policy intervention and 
the control grants not affected by the intervention did not show statistically significant worsening in 
recruitment progress.  The results of sensitivity analyses using alternate measures of recruitment 
success were consistent with main findings.  Reducing the “success” threshold from 100% actual-to-
target to 95%, 90%, and 80% accordingly did not alter the findings.  Only the grantee institution size 
(specifically those institutions receiving at least $400,000,000 in FY2016 NIH funding) was associated 
with a statistically significant increase in odds of meeting recruitment performance milestones. 
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Error z P>|z| 
[95% Confidence 
Interval] 
         
Difference-in-Differences (Policy Effect)1 0.393 0.427 -0.860 0.390 0.047 3.306 
Non-NIMH Clinical Trial FOA2 1.465 1.396 0.400 0.688 0.226 9.486 
Policy Intervention3 4.865 6.881 1.120 0.263 0.304 77.787 
Initial Fiscal Year of Funding 0.324 0.207 -1.770 0.077 0.093 1.130 
NIMH Division 
      
  Division of Translational Research REF REF REF REF REF  REF 
  Office of the NIMH Director 0.786 0.883 -0.210 0.830 0.087 7.103 
  Division of Neuroscience and Basic Behavioral Science 2.225 3.190 0.560 0.577 0.134 36.976 
  Division of Services and Intervention Research 0.735 0.374 -0.600 0.546 0.271 1.994 
  
      
Total Grant Funds Requested 0.995 0.006 -0.860 0.390 0.983 1.007 
ClinicalTrials.gov Registration Reported to NIMH 0.532 0.288 -1.160 0.244 0.184 1.538 
Planned Trial Sample Size 0.999 0.001 -1.360 0.175 0.996 1.001 
Grantee Institution Size4 
      
  X <$100,000,000 USD 
      
  $100,000,000 ≤ X < $200,000,000 1.163 0.649 0.270 0.787 0.389 3.474 
  $200,000,000 ≤ X < $300,000,000 0.506 0.406 -0.850 0.396 0.105 2.443 
  $300,000,000 ≤ X < $400,000,000 5.184 5.134 1.660 0.097 0.744 36.120 
  $400,000,000 ≤ X 4.946 2.801 2.820 0.005* 1.630 15.009 
1Difference-in-Differences for applications changed by policy implementation; 2X=1 if grant application was not 
submitted to NIMH Clinical Trial FOA; 3Revised NIH Clinical Trial Definition;  
4Categorical variable increasing in blocks of $100,000,000 FY2016 NIH funding 
*Significant at the p<0.01 level 
 
Discussion 
 Some researchers and professional groups expressed strong concerns that the revised NIH 
clinical trials definition would overwhelm the newly-identified clinical trials with administrative 
requirements that would delay the research.  Study results do not support the claim that the revised 
clinical trial definition impeded achievement of recruitment targets.  These results suggest that the 
revised policy had no effect on recruitment progress.  This analysis of NIMH-funded clinical trials can be 
used by both the NIMH and the NIH when engaging affected stakeholders to discuss the impact of this 
policy.   
Recruitment progress is a relevant outcome measure for monitoring potential delays in research 
study progress, but it does not represent all implications associated with the revised clinical trial 
definition policy.  This study focused exclusively on potential recruitment delays.  The study did not 
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evaluate associated factors such as researcher stress/burnout, measures of research productivity such 
as the relative citation ratio, or the benefits of increased ClinicalTrials.gov registration and results 
sharing from a larger pool of clinical trials.  These factors should be examined in future research. 
Interestingly, one factor that was significantly associated with a positive increase in odds of on-
target recruitment progress was the size of the grantee institution’s total NIH funding.  Specifically, the 
recipients of very large sums of NIH funding had much higher odds of on-target recruitment 
performance.  Meanwhile, the amount of funding within a single grant or trial did not appear to have 
the same effect.  While this study was not designed to make inferences on the value of individual versus 
total institution funding, it does raise an interesting question for future research.  Does the total NIH 
funding influence a grantee institution’s ability to recruit across all studies and “lift all boats”? 
This study has a number of limitations.  First, the recruitment progress ratio data (dependent 
variable) were analyzed and determined to be non-normally distributed by histogram, Shapiro-Wilk test, 
and Q-Q plot and remained non-normally distributed (low kurtosis) after log-transformation.  The non-
normal distribution of recruitment progress ratios necessitated compression of a continuous variable 
into a binary variable.  Second, only one year of pre-intervention data was available, which does not 
allow for establishing extended pre-intervention trends in recruitment progress in the intervention and 
control arms. Third, as shown in Table 1 and as discussed in the Introduction, the “traditional” clinical 
trials in the control arm are different in nature from the non-traditional clinical trials in the intervention 
arm; in other words, the control arm is not a perfect counterfactual (or an “apples to apples” 
comparison) with the intervention arm.  Fourth, this study did not account for historically high/low 
performing researchers/research teams; density of research participants in a geographic area; or 
different diseases, disorders, or health conditions.  Fifth, this design examined funded grants and did not 
address potential barriers to funding resulting from the policy change.  Finally, the analysis sample was 
limited by the records available in the NIMH Recruitment Milestone Reporting database, which did not 
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capture smaller trials (n<150) prior to FY2017.  The small sample size limited the power of this study to 
detect an effect.  At 80% power, this analysis could only detect an effect greater than a 25% change in 
odds of meeting recruitment progress milestones. 
 
Conclusions 
Numerous NIMH-funded grants that were not classified as clinical trials under the old definition 
were identified as clinical trials under the revised definition.  Many of these grants were basic science or 
mechanistic clinical trials.  Although these newly-classified clinical trials were subject to a range of NIH 
clinical trial policies due to the revised NIH clinical trial definition, this study did not find a negative 
effect on recruitment progress as compared to traditional clinical trials.  Concerns regarding 
administrative delays and burden impacting study progress may be alleviated by these initial results.  
Further research is needed to establish longer before/after trendlines with a larger sample to power 




APS. (2017, June 6, 2017). Re: Clarification of NIH Clinical Trial Policy. Retrieved from 
https://fabbs.org/wp-content/uploads/2017/10/APS-to-Dr.-Collins-re-clinical-trials-policy-6-6-
17.pdf 
APS. (2018). Make Your Voice Heard: Tell NIH You Oppose the Classification of Basic Human Subjects 
Research as Clinical Trials. Retrieved from https://www.psychologicalscience.org/policy/make-
your-voice-heard-tell-nih-you-oppose-the-classification-of-basic-human-subjects-research-as-
clinical-trials.html 
DHHS. (2017). Federal Policy for the Protection of Human Subjects ('Common Rule'). 45 CFR 46. 
Retrieved from https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-
46/index.html 
FABBS. (2017, July 12, 2017). Letter to NIH-Collins Re Clinical Trials. Retrieved from 
https://fabbs.org/wp-content/uploads/2017/08/Letter-to-NIH-Collins-Re-Clinical-Trials-
FINAL.pdf 
Hudson, K. L., Lauer, M. S., & Collins, F. S. (2016). Toward a New Era of Trust and Transparency in Clinical 
Trials. Jama, 316(13), 1353-1354. doi:10.1001/jama.2016.14668 
ICMJE. (n.d.). Clinical Trials Registration. Retrieved from http://www.icmje.org/about-
icmje/faqs/clinical-trials-registration/ 
Insel, T. R., & Gogtay, N. (2014). National Institute of Mental Health clinical trials: new opportunities, 
new expectations. JAMA Psychiatry, 71(7), 745-746. doi:10.1001/jamapsychiatry.2014.426 
Kaiser, J. (2017, July 18, 2017). Some scientists hate NIH’s new definition of a clinical trial. Here's why. 
Science. Retrieved from http://www.sciencemag.org/news/2017/07/some-scientists-hate-nih-s-
new-definition-clinical-trial-heres-why 
Minitab, L. (2019). Goodness-of-fit tests for Simple Binary Logistic Regression. Retrieved from which 
illustrates predicted probabilities do not deviate from the observed probabilities in a way that 
the binomial distribution does not predict, 
NIH. (2014). Notice of Revised NIH Definition of “Clinical Trial”. NOT-OD-15-015. Retrieved from 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html 
NIH. (2016). NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information. NOT-OD-16-149. 
NOT-OD-16-149.  
NIMH. (n.d.). Support for Clinical Trials at NIMH. Retrieved from 
https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-
foas/index.shtml#part_156836 
Reif-Lehrer, L. (2005). Grant Application Writer's Handbook (4th Edition ed.): Jones & Bartlett Learning. 
StataCorp. (2015). Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.  






Integration and Policy Implications 
 
 The first aim of this dissertation identified the new and revised NIH and NIMH clinical trial 
policies from 2005-2019 and summarized the potential benefits and potential burdens of those policies.  
Five new/revised NIH-wide and four NIMH-only clinical trial policies were identified.  The five NIH-wide 
clinical trial policies (1) required planning for post-trial access to antiretroviral treatments; (2) revised 
the clinical trial definition; (3) implemented clinical trial-specific funding opportunity announcements 
(FOA), peer-review criteria, progress reporting; (4) mandated good clinical practice (GCP) training; and 
(5) expanded ClinicalTrials.gov registration and results reporting requirements to all NIH-funded trials.  
The four NIMH-specific clinical trial policies (1) implemented clinical trial-specific FOAs, peer-review 
criteria, progress reporting; (2) established data and safety monitoring requirements; (3) defined 
expectations for oversight by data and safety monitoring boards and independent safety monitors; and 
(4) expanded recruitment progress monitoring and reporting to clinical trials of all sizes. 
Aim 1 also illustrated the perceived benefits and burdens of those clinical trial policies.  Potential 
benefits were the improved identification, review, conduct, and reporting of publicly-funded clinical 
trials.  Potential burdens were loss of researcher time, potential loss of future research funding 
opportunities for basic behavioral researchers, and widespread confusion (for both researchers and the 
general public) resulting from an overlap between clinical trials and basic science. 
NIH developed and implemented these policies to build structure for NIH-funded grants with 
the intent of influencing subsequent processes and outcomes.  Despite this goal, neither the NIH nor the 
NIMH incorporated clear outcome evaluation into these policies.  Without planned evaluation outcomes 
and methods, the NIH and NIMH would struggle to demonstrate that the policies have successfully 
achieved their objectives of improving clinical trials.  Similarly, the NIH and NIMH would have difficulty 
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responding to public concerns that the burdens of compliance outweigh the benefits of the policies.  The 
second and third aims of this dissertation attempted to partially address this gap by evaluating the 
impact of two of these clinical trial policies recruitment performance and relative citation ratio 
outcomes. 
In Aim 2, the impact of the NIH’s clinical trial recruitment policy on mean and maximum relative 
citation ratios was examined by evaluating a similar NIMH-specific recruitment policy that was 
implemented years earlier.  The implementation of the policy was associated with an increased mean 
relative citation ratio, which suggests that the NIH-wide recruitment monitoring policy may also be 
associated with an increased mean relative citation ratio.  While more research is needed to examine 
the specific effects of the NIH-wide policy, these results suggest that the benefits of this policy on the 
relative citation ratio may outweigh the compliance burden.   
In Aim 3, the impact of the revised NIH clinical trial definition on study participant recruitment 
progress was examined by evaluating the impact on NIMH-funded grants.  NIMH-funded grants were 
chosen because the NIMH began identifying and tracking trials that would have met the revised 
definition prior to the policy effective date.  The NIMH grants were also inclusive of the types of 
research (i.e., basic behavioral and social sciences) that raised potential burden concerns in Aim 1.  To 
identify whether the policy led to administrative delays in research, the difference-in-differences for 
odds of on-target recruitment progress was examined in NIMH-funded traditional clinical trials versus 
NIMH-funded clinical trials that were newly-identified by the revised policy.  While the study had 





Cross-cutting Themes and Implications 
 Several cross-cutting themes emerged during this dissertation.  First, the NIH and NIMH should 
prioritize stakeholder engagement and communication early during policy development.  Without 
stakeholder engagement during the policy development, it is likely that certain perspectives, including 
unique perceived burdens, will be underrepresented.  This can limit policy acceptance/adherence and 
reduce the effectiveness of burden minimization.  Once this opportunity has been missed, the policy 
maker’s time and effort are then redirected to addressing these challenges after the fact.  This was 
observed across numerous NIH clinical trial policies. 
Second, a thorough examination of the rationale, potential benefits, and potential burdens 
should be incorporated into policy development.  Policy makers need to clearly articulate the need and 
rationale for a new or revised policy.  This rationale should be weighed against the balance of potential 
benefits and potential burdens and should be carefully considered to maximize the benefits and 
minimize or mitigate the burdens.  The majority of NIH and NIMH clinical trial policies examined in this 
research did not formally solicit feedback from external stakeholders during the development stage. 
Third, while the post-hoc examination of the specific policies in Aims 2 and 3 demonstrated 
positive and neutral outcomes respectively, this may not be the case for all policies or for other 
outcomes of related to these policies.  Policy development must include a priori identification of 
relevant outcomes and a formal plan to evaluate those outcomes.  These outcomes should include both 
the primary focus of the policy as well as metrics to monitor potential burdens.  Without outcome 
evaluation, it is impossible to measure the impact of the potential benefits or potential burdens.  This 
logically leads to an inability to determine whether the policy is a success or a failure.  NIH and NIMH 
need this information when engaging a range of stakeholders including not just the research community 




Need for Future Research 
 The findings of this dissertation do not call for immediate changes to the suite of clinical trial 
policies that have been developed by the NIH and NIMH.  However, this research does illustrate the 
need for improvement in future policy development through increased stakeholder engagement, 
evaluation design, and dissemination.  This dissertation is the first systematic evaluation of the impact of 
NIH and NIMH clinical trial policies, but these analyses were designed post-hoc and limited to research 
funded by NIMH.  Further research and evaluation are needed to continue this investigation.  Future 
research should include broader ranges of science (diseases and disciplines beyond just mental health) 
to be more representative of the NIH research community.  These studies should establish and evaluate 
better grant performance outcome measures that bridge the gap from research scholarship into 
changes in clinical practice.  Finally, future studies should capture larger samples of research grants and 
consider additional covariates such as the effect of disease prevalence within geographic regions on 
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